Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 1 of 74Safety and Immunogenicity of FluzoneÂ®Quadrivalent Vaccine 
Administered to Healthy Children 6 to < 36 Months of Age
Phase IV, randomized, observer-b linded, 2-arm, multi-center trial to evaluate the safety and 
immunogenicity of 2 different dose levels of FluzoneÂ®Quadrivalent vaccine in healthy children 
6 to < 36 months of age
Clinical Trial Protocol, Amendment 1
Health Authority File Number: BB-IND #: 14078
WHO Universal Trial Number (UTN): U1111-1143-9273
Trial Code: GRC88
Development Phase: Phase IV
Sponsor: Sanofi Pasteur Inc.
Discovery Drive, Swiftwat er, PA 18370-0187, USA
Investigational Product: FluzoneÂ®Quadrivalent, Influenza Vaccine (2016â€“2017 formulation)
Form/Route: Liquid/Intramuscular
Indication For This Study: To evaluate the safety and immunogenicity of 2 different dose levels
of Fluzone Quadrivalent vaccine (2016â€“2017 formulation) in children 
6  to < 36 months of age
Manufacturer: Same as Sponsor
Coordinating Investigator: To be determined
Sponsorâ€™s Responsible Medical 
Officers: 
Product Safety Officer:
Clinical Trial Manager:
Version and Date of the Protocol: Version 2.0 dated 13 June 2016
This protocol version 2.0 is the first amendment to the initial trial protocol version 1.0, dated 28 January 2015. 
Information contained in this publication is the property of Sanofi Pasteur and is confidential. This information may not be 
disclosed to third parties without written authorization from Sanofi Pasteur. This document may not be reproduced, stored in a
retrieval system, or transmitted in any fo rm or by any meansâ€“electronic, mechanical  recording, or otherwiseâ€“without prior 
authorization from Sanofi Pasteur. This document mu st be returned to Sanofi Pasteur upon request.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 1 of 75NCT029153 02
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 2 of 74Table of Contents
List of Tables....................................................................................................................................7
Synopsis ............................................................................................................................................8Table of Study Procedures............................................................................................................16List of Abbreviations.....................................................................................................................171 Introduction .....................................................................................................................19
1.1 Background ................................................................................................................. ....19
1.1.1 Epidemiology ............................................................................................................. ..20
1.1.2 Prevention and Control of Infection .............................................................................21
1.1.3 Advisory Committee on Immunizat ion Practices Recommendations..........................21
1.2 Background of the Inve stigational Product.....................................................................22
1.3 Potential Benefits and Risks ...........................................................................................221.3.1 Potential Benefits to Subjects.......................................................................................221.3.2 Potential Risks to Subjects ...........................................................................................22
1.4 Rationale for the Trial..................................................................................................... 23
2 Trial Objectives .............................................................................................................. .27
2.1 Primary Objective ........................................................................................................... 27
2.2 Secondary Objective .......................................................................................................272.3 Observational Objectives................................................................................................28
2.3.1 Safety............................................................................................................................282.3.2 Immunogenicity............................................................................................................ 28
2.3.3 Serum Collection .......................................................................................................... 28
3 Investigators and Trial Organization............................................................................28
4 Institutional Review Board.............................................................................................285 Investigational Plan.........................................................................................................29
5.1 Description of the Overa ll Trial Design and Plan...........................................................29
5.1.1 Trial Design ..................................................................................................................29
5.1.2 Justification of the Trial Design ...................................................................................295.1.3 Trial Plan ................................................................................................................ ......29
5.1.4 Visit Procedures............................................................................................................305.1.5 Planned Trial Calendar .................................................................................................345.1.6 Early Safety Data Review.............................................................................................34Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 2 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 3 of 745.2 Enrollment and Retention of Trial Population................................................................34
5.2.1 Recruitment Procedures................................................................................................34
5.2.2 Informed Consent Procedures ......................................................................................345.2.3 Screening Criteria........................................................................................................ .35
5.2.4 Inclusion Criteria ..........................................................................................................355.2.5 Exclusion Criteria........................................................................................................ .35
5.2.6 Medical History ........................................................................................................... .37
5.2.7 Contraindications for Subsequent Vaccinations...........................................................37
5.2.7.1 Temporary Contraindications.....................................................................................375.2.7.2 Definitive Contraindications ......................................................................................37
5.2.8 Conditions for Withdrawal ...........................................................................................38
5.2.9 Lost to Follow-up Procedures.......................................................................................385.2.10 Classification of Subjects W ho Discontinue the Trial..................................................39
5.2.11 Follow-up of Discontinuations .....................................................................................39
5.3 Safety Emergency Call ...................................................................................................395.4 Modification of the Trial and Protocol ...........................................................................405.5 Interruption of the Trial ..................................................................................................4 0
6 Vaccines Administered ...................................................................................................40
6.1 Identity of the Investigational Product............................................................................41
6.1.1 Identity of Trial Product ...............................................................................................41
6.1.1.1 Composition ............................................................................................................. ..41
6.1.1.2 Preparation and Administration .................................................................................41
6.1.1.3 Dose Selection and Timing ........................................................................................41
6.1.2 Identity of Control Products .........................................................................................42
6.2 Identity of Other Products...............................................................................................426.3 Product Logistics ........................................................................................................... .42
6.3.1 Labeling and Packaging ...............................................................................................42
6.3.2 Product Shipment, Storage, and Accountability...........................................................42
6.3.2.1 Product Shipment .......................................................................................................4 2
6.3.2.2 Product Storage ......................................................................................................... .42
6.3.2.3 Product Accountability...............................................................................................42
6.3.3 Replacement Doses.......................................................................................................436.3.4 Disposal of Unused Products........................................................................................436.3.5 Recall of Products........................................................................................................ .43
6.4 Blinding and Code-breaking Procedures ........................................................................43
6.5 Randomization and Allocation Procedures.....................................................................44
6.6 Treatment Compliance....................................................................................................456.7 Concomitant Medications and Other Therapies .............................................................45Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 3 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 4 of 747 Management of Samples.................................................................................................46
7.1 Sample Collection...........................................................................................................46
7.2 Sample Preparation .........................................................................................................467.3 Sample Storage and Shipment ........................................................................................477.4 Future Use of Stored Serum Samples for Research........................................................47
8 Clinical Supplies ............................................................................................................. .47
9 Endpoints and Assessment Methods .............................................................................48
9.1 Primary Endpoints and Assessment Methods.................................................................48
9.1.1 Safety............................................................................................................................48
9.1.1.1 Safety Endpoints ........................................................................................................489.1.1.2 Safety Assessment Methods.......................................................................................48
9.1.2 Immunogenicity............................................................................................................ 48
9.1.3 Efficacy.........................................................................................................................48
9.2 Secondary Endpoints and Assessment Methods.............................................................48
9.2.1 Safety............................................................................................................................489.2.2 Immunogenicity............................................................................................................ 49
9.2.2.1 Immunogenicity Endpoints ........................................................................................49
9.2.2.2 Immunogenicity Assessment Methods ......................................................................49
9.2.3 Efficacy.........................................................................................................................49
9.3 Observational Endpoints and Assessment Methods .......................................................49
9.3.1 Safety............................................................................................................................49
9.3.1.1 Safety Definitions...................................................................................................... .50
9.3.1.2 Safety Endpoints ........................................................................................................52
9.3.1.3 Safety Assessment Methods.......................................................................................539.3.1.3.1 Immediate Post-vaccination Surveillance Period ....................................................53
9.3.1.3.2 Reactogenicity (Solicite d Reactions From Day 0 to Day 7 After Each 
Vaccination).............................................................................................................53
9.3.1.3.3 Unsolicited Non-serious Adverse Events From Visit 1 to Visit 2 or Visit 3...........57
9.3.1.3.4 Serious Adverse Events ...........................................................................................589.3.1.3.5 Adverse Events of Special Interest ..........................................................................58
9.3.1.3.6 Assessment of Causality ..........................................................................................58
9.3.2 Immunogenicity............................................................................................................ 59
9.3.2.1 Immunogenicity Endpoints ........................................................................................59
9.3.2.2 Immunogenicity Assessment Methods ......................................................................59
9.3.3 Efficacy.........................................................................................................................59
9.3.4 Serum Collection .......................................................................................................... 59
9.3.4.1 Serum Collection Endpoints and Assessment Methods.............................................60
10 Reporting of Serious Adverse Events............................................................................60Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 4 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 5 of 7410.1 Initial Reporting by the Investigator...............................................................................60
10.2 Follow-up Reporting by the Investigator........................................................................61
10.3 Reporting of SAEs Occurring After a Subject Has Completed the Study......................61
10.4 Assessment of Causality .................................................................................................6110.5 Reporting SAEs to Health Authorities and IECs/IRBs...................................................61
11 Data Collection and Management .................................................................................62
11.1 Data Collection and eCRF Completion ..........................................................................62
11.2 Data Management ...........................................................................................................6311.3 Data Review....................................................................................................................63
12 Statistical Methods and Determination of Sample Size...............................................64
12.1 Statistical Methods..........................................................................................................64
12.1.1 Hypotheses and Statistical Met hods for Primary Objective.........................................64
12.1.1.1 Hypothesis..................................................................................................................64
12.1.1.2 Statistical Methods.................................................................................................... .64
12.1.2 Hypotheses and Statistical Met hods for Secondary Objective.....................................64
12.1.2.1 Hypotheses .................................................................................................................64
12.1.2.2 Statistical Methods.................................................................................................... .65
12.1.3 Statistical Methods for Observational Objectives ........................................................6512.1.3.1 Safety..........................................................................................................................65
12.1.3.2 Immunogenicity ......................................................................................................... 65
12.2 Analysis Sets...................................................................................................................66
12.2.1 Safety Analysis Set...................................................................................................... .66
12.2.2 Full Analysis Set...........................................................................................................6612.2.3 Per-Protocol Analysis Set.............................................................................................6612.2.4 Populations Used in Analyses ......................................................................................67
12.3 Handling of Missing Data and Outliers ..........................................................................67
12.3.1 Safety............................................................................................................................6712.3.2 Immunogenicity........................................................................................................... .67
12.4 Interim/Preliminary Analysis..........................................................................................67
12.5 Determination of Sample Size and Power Calculation...................................................67
13 Ethical and Legal Issues and Investigator/Sponsor Responsibilities..........................68
13.1 Ethical Conduct of the Tria l/Good Clinical Practice ......................................................68
13.2 Source Data and Source Documents...............................................................................68
13.3 Confidentiality of Data and Access to Subject Records .................................................6813.4 Monitoring, Auditing, and Archiving .............................................................................69Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 5 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 6 of 7413.4.1 Monitoring....................................................................................................................69
13.4.2 Audits and Inspections .................................................................................................70
13.4.3 Archiving......................................................................................................................70
13.5 Financial Contract and Insurance Coverage ...................................................................7013.6 Stipends for Participation................................................................................................7 0
13.7 Publication Policy ......................................................................................................... ..70
14 References List.............................................................................................................. ...72
15 Signature Pages .............................................................................................................. .74Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 6 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 7 of 74List of Tables
Table 9.1: Solicited Injection Si te Reactions: Terminology, Definitions, and Intensity Scales 
(Subjects 6 to < 36 Months of Age) ................................................................................................55
Table 9.2: Solicited Systemic Reactions: Terminol ogy, Definitions, and Intensity Scales (Subjects 
6 to < 36 Months of Age) ................................................................................................................56Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 7 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 8 of 74Synopsis
Company: Sanofi Pasteur
Licensed Product: FluzoneÂ®Quadrivalent, Influenza Vaccine
(2016â€“2017 Formulation)
Active Substances: Influenza virus surface antigen s of the following strains:
xA/California/7/2009 X-179A (H1N1) 
xA/Hong Kong/4801/2014 X-263B (H3N2) 
xB/Brisbane/60/2008 (Victoria lineage; B1)
xB/Phuket/3073/2013 (Y amagata lineage; B2)
Title of the Trial: Safety and Immunogenicity of FluzoneÂ®Quadrivalent Vaccine 
Administered to Healthy Children 6 to < 36 Months of Age
Development Phase: Phase IV
Coordinating Investigator: To be determined
Trial Centers: This will be a multi-center trial conducted in the United States. 
Investigators and sites are listed in the â€œList of Investigators, Trial Centers, 
and Sponsorâ€™s Personnel Involved in the Trialâ€ document.
Planned Trial Period: First Visit, First Subject: September 2016
Last Visit, Last Subject: February 2017
Trial Design and Methodology: This will be a Phase IV, randomized, observer-blinded, 2-arm, multi-center 
trial of approximately 2190 subjects 6 to < 36 months of age. Using a pre-programmed interactive response technology (IRT) system, 
subjects will be randomly assigned in a 1:1 ratio to either 1 of the following groups:
Group 1: 0.25 mL of Fluzone Quadrivalent vaccine (approximately 1095 
subjects)
Group 2: 0.5 mL of Fluzone Quadrivalent vaccine (approximately 1095 
subjects) 
Enrollment will be stratified by age at each site so that approximately 50% of 
subjects at each site will be 6 to < 24 months of age and approximately 50% 
of subjects at each site will be 24 to < 36 months of age. If necessary to 
achieve 50% overall enrollment of su bjects 6 to < 24 months of age, 
individual sites may be permitted to deviate from this ratio. 
All subjects will receive 1 intramuscular dose of Fluzone Quadrivalent 
vaccine during Visit 1. For subjects for whom 2 doses of influenza vaccine are recommended per the Advisory Committee on Immunization Practices 
(ACIP) guidance, a second dose of Fluzone Quadrivalent vaccine will be 
administered during Visit 2 (28 [window, 28â€“35] days after Visit 1). Blood 
specimens will be obtained from a planne d subset of 1600 subjects randomly 
selected by an IRT system (half in Group 1 and half in Group 2) prior to the 
first vaccination and 28 (window, 28â€“35) days following the final vaccination (Visit 2 for subjects receiving 1 dose; Visit 3 for subjects 
receiving 2 doses) and assayed for immunogenicity.
Solicited adverse event (AE) information will be collected for 7 days after 
each vaccination. Unsolicited AE info rmation and serious adverse event Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 8 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 9 of 74(SAE) information will be collected from Visit 1 to Visit 2 for subjects 
receiving 1 dose or from Visit 1 to Vi sit 3 for subjects receiving 2 doses. 
Note: Any SAE that occurs after a subject has completed the study but that is 
likely to be related to the product is to also be reported to the Sponsor.
The subject, Investigator, study site pers onnel, and Sponsorâ€™s clinical team 
members involved in the trial will be blinded to the vaccine dose 
administered, with the exception of 1 or more unblinded qualified study staff 
members who will administer the vaccine. The unblinded qualified study 
staff will not participate in the collection of safety data.
Early Safety Data Review: This trial will not include an early review of safety data. However, it may be interrupted at any time if new data about the investigational product become available, and/or on advice of the Sponsor, the Institutional Review Board(s) 
(IRB[s]), or the Food and Drug Administration (FDA). 
If the trial is prematurely terminated or suspended, the Sponsor will promptly 
inform the Investigators, the IRB(s), and the FDA of the reason for termination or suspension. If the trial is prematurely terminated for any reason, the Investigator will prom ptly inform the trial subjectsâ€™ 
parents/guardians and should assure appropriate therapy for and follow-up ofsubjects.
Primary Objective: 7RFRPSDUHWKHUDWHRIDQ\IHY HUWHPSHUDWXUHÂ•Âƒ)>oC]) following 
the 0.5-mL dose of Fluzone Quadrivalent vaccine to that following the 0.25-mL dose of Fluzone Quadrivalent vaccine during the 7 days after either 
vaccination (Dose 1 and Dose 2 combined) in subjects 6 to < 36 months of 
age.
Hypothesis: 
During the 7 days after either vaccination (Dose 1 and Dose 2 combined), the 
0.5-mL dose of Fluzone Quadrivalent vaccine will be non-inferior to the 0.25-mL dose of Fluzone Quadrivalent vaccine in terms of fever reaction 
(temperature Â•Âƒ)>
oC]) in subjects 6 to < 36 months of age.
Primary Endpoints: RatesRIDQ\IHYHUWHPSHU DWXUHÂ•Âƒ)>oC]) during the 7 days after 
either vaccination (Dose 1 and Dose 2 combined) in each vaccine group.
Secondary Objective: To compare antibody responses induced by the 0.5-mL dose of Fluzone 
Quadrivalent vaccine to those induce d by the 0.25-mL dose of Fluzone 
Quadrivalent vaccine as assessed by  geometric mean titer (GMT) ratios and 
seroconversion rate differences after th e final vaccination in subjects 6 to 
< 36 months of age.
Hypotheses:
Geometric mean titers : For each of the 4 virus strains, the post-final 
vaccination GMTs in subjects 6 to < 36 months of age who receive the 
0.5-mL dose of Fl uzone Quadrivalent vaccine w ill be non-inferior to the 
post-final vaccination GMTs in those subjects who receive the 0.25-mL dose 
of Fluzone Quadrivalent vaccine.
Seroconversion : For each of the 4 virus strains,  the seroconversion rates in 
subjects 6 to < 36 months of age wh o receive the 0.5-mL dose of Fluzone 
Quadrivalent vaccine will be non-inferior to the sero conversion rates in those 
subjects who receive the 0.25-mL dose of Fluzone Quadrivalent vaccine.
Secondary Endpoints: xGeometric mean titers: The hemagglutination inhibition (HAI) GMTs 
(for each of the 4 virus strains) at 28 (window, 28â€“35) days after the 
final vaccination.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 9 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 10 of 74xSeroconversion rates: The percentage s of subjects with either a pre-
vaccination titer < 10 (1/dil) and a post-vaccination titer Â•40 (1/dil), or a 
pre-vaccination titer Â•10 (1/dil) and a Â•4-fold increase in post-
vaccination titer at 28 (window, 28â€“35 ) days after the final vaccination.
Observational Objectives: Safety
To describe the safety of 2 different dose levels of the 2016â€“2017 
formulation of Fluzone Quadrivalent vaccine in subjects 6 to < 36 months of 
age. 
Immunogenicity
To describe the immunogenicity of 2 different dose levels of the 2016â€“2017 
formulation of Fluzone Quadrivalent vaccine in subjects 6 to < 36 months of 
age. 
Serum Collection
To submit available sera from approxim ately 30 subjects to the Center for 
Biologics Evaluation and Research for further analysis by the World Health 
Organization, the Centers for Disease Control and Prevention, and the FDA 
to support formulation recommendations for subsequent influenza vaccines.
Observational Endpoints: Safety
1) Occurrence, nature (Medical Dictionary for Regulatory Activities 
[MedDRA] preferred term), duration, intensity, and relationship to 
vaccination of any unsolicited systemic  AEs reported in the 20 minutes 
after each vaccination.
2) Occurrence, time to onset, number of days of occurrence, intensity, 
action taken, and whether the reaction led to early termination from the study, of solicited injection site r eactions (prelisted in the subjectâ€™s 
diary card and electronic case report form [eCRF]) occurring between Day 0 and Day 7 after each vaccination.
3) Occurrence, time to onset, number of days of occurrence, intensity, 
action taken, and whether the reaction led to early termination from the study, of solicited systemic reactions (prelisted in the subjectâ€™s diary card and eCRF) occurring between Day 0 and Day 7 after each 
vaccination.
4) Occurrence, nature (MedDRA prefe rred term), time to onset, duration, 
intensity, action taken, relationship to vaccination (for systemic AEsonly), and whether the event led to early termination from the study, of 
unsolicited AEs between Visit 1 and Visit 2 for subjects receiving 1 dose or between Visit 1 and Visit 3 for subjects receiving 2 doses.
5) Occurrence, nature (MedDRA preferred term), time to onset, 
seriousness criteria, relationship to vaccination, outcome, and whether 
the SAE led to early termination from the study, of SAEs between 
Visit 1 and Visit 2 for subjects receiving 1 dose or between Visit 1 and Visit 3 for subjects receiving 2 doses.
Adverse events of special interest will be captured as SAEs. These includenew onset of Guillain-BarrÃ© syndrome (GBS), encephalitis/myelitis(including transverse myelitis), neur itis (including Bellâ€™s palsy, optic 
neuritis, and brachial neuritis), thrombocytopenia, vasculitis, convulsions 
(including febrile convulsions), and anaphylaxis or other 
hypersensitivity/allergic reactions between Visit 1 and Visit 2 for subjects receiving 1 dose, or between Visit 1 and Visit 3 for subjects receiving 
2 doses.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 10 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 11 of 74Immunogenicity
Immunogenicity will be evaluated in a subset of 1600 randomly selected 
subjects prior to vaccination on Day 0 (Visit 1) and at 28 (window, 28â€“35) 
days after the final vaccination using the HAI technique. For each influenza 
vaccine strain, HAI assay titers at  pre-vaccination (Day 0) and at 
28 (window, 28â€“35) days after the final vaccination will be determined in 
duplicate.
The derived endpoints are:
xGeometric means of HAI assay titers for individual subjects at pre-
vaccination (Day 0) and at 28 (windo w, 28â€“35) days after the final 
vaccination.
xRatios of individual post-final vaccination titers divided by individual 
pre-vaccination titers.
x6HURSURWHFWLRQVXEMHFWVZLWKDWLWHUÂ• 40 (l/dil) at pre-vaccination or at 
28 (window, 28â€“35) days after the final vaccination.
xSeroconversion: subjects with either  a pre-vaccination titer < 10 (1/dil) 
and a post-vaccination titer Â•40 (1/dil), or a pre-vaccination titer 
Â•10 (1/dil) and a Â•4-fold increase in post-vaccination titer at 28 
(window, 28â€“35) days after the final vaccination.
Serum Collection
There are no observational endpoints or statistical methods for this 
objective.
Planned Sample Size: This study will enroll approximately 2190 subjects 6 to < 36 months of age:
Group 1 (0.25 mL of Fluzone Quadri valent vaccine): approximately 1095
subjects
Group 2 (0.5 mL of Fluzone Quadrivalent vaccine): approximately 1095 
subjects 
Schedule of Study Procedures: Vaccination
All subjects will receive 1 intramuscula r injection of Fluz one Quadrivalent 
vaccine (0.25 mL [Group 1]  or 0.5 mL [Group 2]) at  Visit 1. For subjects for 
whom 2 doses of influenza vaccine are recommended per ACIP guidance, a 
second intramuscular injection of influenza vaccine (same 0.25-mL or 
0.5-mL dose as administered at Visit 1 ) will be administered at Visit 2. 
Blood Sampling
A total of 2 blood samples of appr oximately 5 mL each will be collected 
from a planned subset of 1600 subjects ra ndomly selected by an IRT system 
(half in Group 1 and half in Group 2). 
The first blood sample will be collected at Visit 1 prior to vaccination. The 
second blood sample will be collected at Visit 2, if no study vaccine is 
administered at Visit 2; or at Visit 3,  if study vaccine is administered at 
Visit 2.
Study sites, at their discretion, may apply a topical analgesic to the 
venipuncture site prior to obtaining sera. However, topical analgesic agents must not
be applied at the site of vaccine administration.
Collection of Safety Data
Staff will observe subjects for 20 minutes following vaccine administration 
and will record the occurrence of any immediate unsolicited systemic AEs.
Parents/guardians will record information about solicited injection site and Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 11 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 12 of 74systemic reactions from Day 0 to Day 7 after each vaccination, and will 
record information about unsolicite d non-serious AEs and SAEs from 
Visit 1 to Visit 2 for subjects receiving 1 dose of study vaccine and from 
Visit 1 to Visit 3 for subjects receiving 2 doses of study vaccine.
xStaff will contact parents/guardians by telephone at Day 8 (window, 
Days 8â€“10) after any study vaccine administration to remind
parents/guardians to record any AEs experienced and any concomitant 
medications taken from the most recent visit to the next visit in the diary 
card and to bring the diary card with them to the next visit. 
Parents/guardians will also be reminded to notify the site immediately if 
an SAE occurs.
xStaff will review the safety data w ith parents/guardians at Visit 2 for 
subjects receiving 1 dose of study vacc ine, or at Visit 2 and Visit 3 for 
subjects receiving 2 dose s of study vaccine.
Duration of Participation in the 
Trial:xFor subjects receiving only 1 dose of Fluzone Quadrivalent vaccine: 28 (window, 28â€“35) days following the dose of influenza vaccine
xFor subjects receiving 2 doses of Fluzone Quadrivalent vaccine: 28 (window, 28â€“35) days following the second dose of influenza 
vaccine 
xNo additional safety follow-up beyond Visit 2 (for subjects receiving 
1 dose) or Visit 3 (for subjects receiving 2 doses) is planned
Licensed Product: Fluzone Quadrivalent vaccine, No Preservative: Pediatric Dose (0.25-mL 
dose), 2016â€“2017 formulation 
or
Fluzone Quadrivalent vaccine, No Pr eservative (0.5-mL dose), 2016â€“2017
formulation
Form: Liquid â€“ pre-filled syringes
Composition: Each 0.25-mL dose contains 7.5 Î¼g hemagglutinin (HA) of each antigen, 
and each 0.5-mL dose contains 15 Î¼g HA of each antigen:
xA/California/07/2009 X-179A (H1N1) 
xA/Hong Kong/4801/2014 X-263B (H3N2) 
xB/Brisbane/60/2008 (Victoria lineage; B1)
xB/Phuket/3073/2013 (Yamagata lineage; B2)
Route: Intramuscular
Batch Number: TBD
Inclusion Criteria: An individual must fulfill allof the following criteria in order to be eligible 
for trial enrollment:1) Aged 6 to < 36 months of age on the day of first study vaccination 
(study product administration).
2) BRUQDWIXOOWHUPRISUHJQDQF\Â•ZHHNVDQGRUZLWKDELUWK ZHLJKW
Â•NJ
Note: This inclusion criterion only applies to subjects 6 to < 12 months 
of age on the day of the first study visit.
3) Informed consent form has been signed and dated by the parent(s) or 
guardian(s).
4) Subject and parent/guardian are able to attend all scheduled visits and Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 12 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 13 of 74to comply with all trial procedures.
Exclusion Criteria: An individual fulfilling any of the following criteria is to be excluded from 
trial enrollment:
1) Participation at the time of study enrollment (or in the 30 days 
preceding the first trial vaccination) or planned participation during the 
present trial period in another clin ical trial investigating a vaccine, 
drug, medical device, or medical procedure. 
Note: Subjects may be considered eligible for enrollment if no 
intervention for the other study occurred within the 30 days prior to the 
first study vaccination and none are planned before the subject would 
complete safety surveillance for the present study.
2) Receipt of any vaccine in the 30 days preceding the first trial 
vaccination, or planned receipt of any vaccine before Visit 2 for 
subjects receiving 1 dose of influenz a vaccine or Visit 3 for subjects 
receiving 2 doses of  influenza vaccine.
3) Previous vaccination against influenza (in the 2016â€“2017 season) with 
either the trial vaccine or another vaccine.
4) Receipt of immune globulins, blood, or blood-derived products in the 
past 3 months.
5) Known or suspected congenital or acquired immunodeficiency; or 
receipt of immunosuppressive th erapy, such as anti-cancer 
chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for 
more than 2 consecutive weeks within the past 3 months).
6) Known systemic hypersensitivity to any of the vaccine components, or 
history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
Note : the list of vaccine components is included in the Prescribing 
Information.
7) Thrombocytopenia, which may be a contraindication for intramuscular 
vaccination, at the discre tion of the Investigator.
8) Bleeding disorder, or receipt of anticoagulants in the 3 weeks 
preceding inclusion, contraindicating intramuscular vaccination.
9) Deprived of freedom by an administrative or court order, or in an 
emergency setting, or hospitalized involuntarily.
10) Chronic illness that, in the opinion of the Investigator, is at a stage 
where it might interfere with trial conduct or completion. 
11) Moderate or severe acute illness/infection (according to Investigator 
judgment) on the day of planned vaccination or febrile illness 
(temperatur HÂ•100.4Â°F [38.0
oC]). A prospective subject should not be 
included in the study until the condition has resolved or the febrile 
event has subsided.
12) Identified as a natural or adopted child of either the Investigator or an 
employee with direct involvement in the proposed study.
13) History of serious adverse reaction to any influenza vaccine.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 13 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 14 of 7414) Personal history of GBS.
15) Any condition that in the opinion of the Investigator would pose a 
health risk to the subject if enrolled or could interfere with the 
evaluation of the vaccine.
16) Personal history of clinically significant developmental delay (at the 
discretion of the Investigator), neurologic disorder, or seizure disorder.
17) Known seropositivity for human immunodeficiency virus, hepatitis B, 
or hepatitis C.
Note: Subjects enrolled into this st udy will not be proh ibited from donating 
blood for non-interventional studies or other purposes.
Statistical  Methods: Summaries of the recruitm ent and baseline demograp hic characteristics of 
the study subjects will be presented. The number of subjects enrolled and 
their age at enrollment (mean, median, and minimum and maximum), sex, 
race, and ethnic origin will be summarized, alon g with the number and 
description of protocol violations.
Continuous variables will be summarized by descriptive statistics (e.g., 
means and standard deviations for the non-immunogenicity endpoints, and 
geometric means and their confid ence intervals [CIs] for the 
immunogenicity endpoints); categorical  variables will be summarized by 
frequency distributions (frequency counts, percentages, and their CIs for the 
main endpoints).
Primary Objective: Safety
The 0.5-mL dose of Fluzone Quadrivalent vaccine will be demonstrated as 
non-inferior to the 0.25-mL dose of Fluzone Quadrivalent vaccine in terms 
of fever reaction through an assessment of the rates of any fever WHPSHUDWXUHÂ•Âƒ)>
oC]) during the 7 days following any dose 
(Dose 1 and Dose 2 combined). Non-inferiority will be demonstrated if the 
upper bound of the 2-sided 95% CI of the rate difference between Group 2
(subjects receiving 0.5 mL of vaccine) and Group 1 (subjects receiving 0.25 mL of vaccine) is < 5%. The 95% CI of the rate difference will be computed 
using the Wilson Score method without continuity correction. The Safety 
Analysis Set will be used for this objective.
Secondary Objective: Immunogenicity
Geometric mean titers:
The statistical methodology will be based on a 
2-sided 95% CI of the ratio of the GMTs (0.5-mL dose divided by 0.25-mL 
dose) at 28 (window, 28â€“35) days after the final vaccination.  Non-
inferiority for GMTs will be demonstrated if the lower limit of the 2-sided 95% CI of the GMT ratio is > 0.667 fo r each of the 4 virus strains. The 95%
CI will be calculated using normal appr oximation of log-transformed titers.
The Per-Protocol Analysis Set (PPAS) will be used as the primary analysis 
set for this objective.
Seroconversion :
The statistical methodology will be based on a 2-sided 
95% CI of the difference in seroconversion rates (0.5-mL dose minus 0.25-
mL dose) at 28 (window, 28â€“35) days after the final vaccination. Non-inferiority for seroconversion will be demonstrated if the lower limit of the 
2-sided 95% CI is > -10% for the 4 strains. The 95% CI of the rate 
difference will be computed usin g the Wilson Score method without 
continuity correction. The PPAS will be used as the primary analysis set for 
this objective.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 14 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 15 of 74Observational Objectives
Safety
The Safety Analysis Set will be used for the safety analyses. All analyses 
will be descriptive; no hypotheses will be tested.
For the main parameters, 95% CIs of point estimates will be calculated using the exact binomial distribution (Clopper-Pearson method) for proportions.
Immunogenicity
The following immunogenicity parame ters will be calculated for each 
influenza strain with 95% CIs of point estimates calculated using the exact 
binomial distribution (Clopper-Pearson method) for proportions and using 
normal approximation for GMTs: 
xGeometric mean HAI assay titers at pre-vaccination (Day 0) and at 
28 (window, 28â€“35) days after the final vaccination.
xGeometric means of the individual titer ratios of post-final 
vaccination/pre-vaccination.
x6HURSURWHFWLRQUDWHV7KHSHUFHQWDJHVRIVXEMHFWVZLWKDWLWHU Â•40 (l/dil) 
at pre-vaccination and at 28 (window, 28â€“35) days after the final vaccination.
xSeroconversion rates: The percentages of subjects with either a pre-
vaccination titer < 10 (1/dil) and a post-vaccination titer Â•40 (1/dil), or 
a pre-vaccination titer Â•10 (1/dil) and a Â• 4-fold increase in post-
vaccination titer at 28 (window, 28â€“35 ) days after the final vaccination.
Sample size determinationSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 15 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 16 of 74Table of Study Procedures
Trial Flow Chart for Subjects 6 to < 36 Months of Ag e: 2 or 3 Visits, 1 or 2 Vaccinations, 2 Groups
All Sub jectsSubjects Receiving 1 Dose of 
Influenza Vaccine Subjects Receivin g 2 Doses of Influenza Vaccine
Visit NumberVisit 1Telephone 
Contact Visit 2 Visit 2 Tel ephone Contact Visit 3
Trial Timelines Day 0 Visit 1 + 8 days Visit 1 + 28 days Visit 1 + 28 days Visit 2 + 8 days Visit 2 + 28 days
Time Windows -- + 8 to 10 days + 28 to 35 days + 28 to 35 days + 8 to 10 days + 28 to 35 days
Informed consent X
Inclusion & Exclusion Criteria X
Demographic data X
Medical history X
Influenza vaccination history X
History-directed physical examination X X
Temperature X X
Allocation of subject 
number/RandomizationX
Blood sample (BL)aBL1 BL2 BL2
Vaccinationb,cXX
Immediate surveillance (20 minutes) X X
Diary card (DC) provided DC1 DC2
Telephone contactdXX
Diary card reviewed and collected DC1 DC1 DC2
Interim history XX X
Termination recordeXX
Serious adverse events To be reported throughout the study period
aA blood sample, approximate ly 5 mL, will be collected from s ubjects randomly assigned to the im munogenicity subset at Visit 1, p rior to vaccination, and at either Visit 2 (for subjects receiving 1 
influenza vaccine dose) or at Visit 3 (for s ubjects receiving 2 influenza vaccine doses).
bGroup 1 will receive a 0.25-mL dose of Fluzone Quadrivalent vaccine at Day 0; Group 2 w ill receive a 0.5-mL dose of Fluzone Qua drivalent vaccine at Day 0. 
cOne or 2 doses of influenza vaccine will be administered according to the Advisory Co mmittee on Immunization Practices guidance in effect during the study. If 2 doses of influenza vaccine are 
indicated, 1 dose will be administered during Visit 1 and the second dose (of the same volume as the first dos e) will be adminis tered approximately 28 days later during Visit 2.
dThe subjectâ€™s parent/guardian will be contac ted by telephone on Day 8 after vaccination as a reminder to complete the diary car d and to bring it with them to the next visit.
eThe termination form will be completed at Visit 2 for subjects receiving 1 dose of infl uenza vaccine or at Visit 3 for subjects  receiving 2 doses of influenza vaccine. Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 16 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 17 of 74List of Abbreviations
ACIP Advisory Committee on Immunization Practices
AE Adverse Event
AR Adverse Reaction
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention
CDM Clinical Data Management
CI Confidence Interval
CRA Clinical Research Associate
CTA Clinical Trial Agreement
eCRF Electronic Case Report Form
EDC Electronic Data Capture
FAS Full Analysis Set
FDA Food and Drug Administration
FVFS First Visit, First Subject
GBS Guillain-BarrÃ© Syndrome
GCI Global Clinical Immunology
GCP Good Clinical Practice
GMT Geometric Mean Titer
GPV Global PharmacoVigilance 
HA Hemagglutinin
HAI Hemagglutination Inhibition
ICF Informed Consent Form
ICH International Confer ence on Harmonisation
IIV3 Trivalent Inactivated Influenza Vaccine
IND Investigational New Drug (application)
IRB Institutional Review Board
IRT Interactive Response Technology
LLT Lowest Level Term
LLOQ Lower Limit of Quantification
LVLS Last Visit, Last Subject
MedDRA Medical Dictionary for Regulatory Activities
NA Neuraminidase
NACI National Advisory Committee on Immunization
PICU Pediatric Intensive Care Unit
PPAS Per-Protocol Analysis SetSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 17 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 18 of 74PSO Product Safety Officer
RBC Red Blood Cell
RMO Responsible Medical Officer
SAE Serious Adverse Event
TMF Trial Master File
ULOQ Upper Limit of Quantification
WHO World Health OrganizationSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 18 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 19 of 741 Introduction
1.1 Background
This is a trial using the 2016â€“2017 formulation of  quadrivalent inactivated influenza vaccine 
(FluzoneÂ® Quadrivalent, Influenza Vaccine). 
Influenza viruses types A and B belong to the genus Orthomyxoviridae and are characterized as 
enveloped, negative-strand, segmented RNA viruses.  The viral envelope contains 2 virus-coded 
glycoprotein spikes, the hemagglutinin (HA) a nd neuraminidase (NA) proteins, which are key 
antigens in the host response to influenza virus in both natural infection and vaccination. A third 
protein, M2, is a minor envelope co mponent of the A-strain viruses (1) (2).
Influenza is transmitted through inhalation of virus- containing droplets from infected individuals. 
The incubation period is usually 1 to 2 days  (3). The virus multiplies in the ciliated columnar 
epithelium of the upper- and lower-respiratory tract, causing cellular necrosis and sloughing  (2).
Virus shedding typically begins just before il lness onset (within 24 hour s), rapidly peaks, and 
remains elevated for 1 to 2 days before rapidl y declining to low levels . Usually, virus shedding 
lasts a total of 5 to 10 days (3).
There is considerable variation in the severity of i llness in different individu als, partly due to age, 
general health, and immune status relative to previous influenza infectio ns. The classic symptoms 
include rapid onset (12 hours or le ss) of malaise, fever, myalgia,  headache, and a non-productive 
cough or sore throat. Most symptoms last severa l days, but malaise and cough may last for a week 
or more (3).  Complications of influenza include prim ary viral pneumonia, secondary bacterial 
pneumonia, and exacerbation of underlying medical conditions such as chronic obstructive 
pulmonary disease and congestive heart failure.
While influenza affects all age groups, the elde rly and persons with underlying health problems 
are at increased risk for complications. Memb ers of high-risk groups who become ill with 
influenza are more likely than the general popul ation to require hospita lization. Among infants 
and younger children, estimated rates of influenza- associated hospitalizat ion are substantially 
higher than among older children an d are similar to rates for other groups considered at higher 
risk for influenza- UHODWHGFRPSOLFDWLRQVLQFOXGLQJSHUVRQVDJHGÂ•  65 years  (1).
Antigenic variation is an important feature of the influenza virus. The viral HA and NA surface 
antigens are subject to continuous and sequential evolution within immune or partially immune 
populations. Antigenic drift results from mutation(s)  affecting the RNA segment coding for either 
HA or NA, but more commonly HA. As a result, th ere is alteration in pr otein structure involving 
1 or a few amino acids, resulting in minor change s in antigenicity. Antigenic variants within a 
subtype (e.g., H1 or H3) emerge and through na tural selection gradua lly become the more 
predominant circulating virus strain, while th e preceding antigenic variant is suppressed by 
specific immunity in the population. In contrast to antigenic drift, antigenic shift represents the 
emergence of completely new subtypes, typi cally through gene reassortment with other 
circulating strains and acquisition of antigenically different gene sequences. Antigenic shift 
occurs at irregular interval s and may lead to pandemics  (2) (3). While influenza B appears to be 
more genetically stable than influenza A, the dom inant circulating B strain typically varies from Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 19 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 20 of 74season to season. For over a decade, both Yamagata  and Victoria lineages  have co-circulated
during each season with  varying prevalence (4).The large antigenic divergence between the 
2 influenza B lineages limits antig enic cross-reactivity, and immun ity to influenza viruses of 
1 B lineage may not provide adequate protection agai nst viruses of the other lineage. Accordingly, 
switching from a trivalent vaccine to a quadrivalen t vaccine is expected to prevent additional 
morbidity and mortality associated with influenza B  (4). With this in mind, Fluzone Quadrivalent 
vaccine was developed.
1.1.1 Epidemiology
Influenza is noted for occurring in epidemics. Typically, localized influenza epidemics begin
abruptly, peak in 2 to 3 weeks, and last 5 to 6 weeks. The first sign of in fluenza in the community 
is usually reports of increased numbers of children with febrile respiratory illness, although a 
nursing home outbreak may be the fi rst indication. Outbreaks in ch ildren are usually followed by 
the occurrence of influenza-like illness among adults. Following this  is an increase in hospital 
admissions for pneumonia, exacerbation of chr onic obstructive pulmonary disease, croup, and 
congestive heart failure. Increase d absenteeism from school and th e workplace occurs as a late 
indicator. Finally, an increased number of deat hs due to pneumonia and influenza are a highly 
specific indicator of influenza. However, due to the reporting delay and time course from 
infection to death, this indi cator lags behind the others (3).
As with other viral respiratory infections, influenza is a seasonal disease. In the Northern 
Hemisphere, influenza is most likely to occur from November to April, and in the Southern Hemisphere from May to October. In tropical regions, it is more endemic, with periods of 
increased activity occurring more than once a year. 
The public health impact of influenza is dramatic. Estimated rates of influenza-associated 
hospitalization are substantially higher among infants and younger children than among older children and are similar to rates for other groups considered at higher risk  for influenza-related 
FRPSOLFDWLRQVLQFOXGLQJSHUVRQVDJHGÂ•\HDUV'XULQJ â€“2008, the estimated rate of 
influenza-associated hospita lizations was 91.5 per 100,000 among children aged < 1 year and 
21.9 per 100,000 for children aged 1 through 4 year s. Annual hospitalizati on rates for influenza 
decrease with increasing age, ranging from  240â€“720 hospitalizations per 100,000 children aged 
< 6 months to approximately 20 hospitalizati ons per 100,000 children aged 2 through 5 years. 
Hospitalization rates for children aged < 5 years with high-risk medical conditions are higher, 
with estimates of 250â€“500 hospitalizations  per 100,000 children in some studies (1).
In the United States, death associated with la boratory-confirmed influe nza virus infection among 
children aged < 18 years has been a nationally  reportable condition si nce 2004. Since reporting 
began, the annual number of influenza-associated  pediatric deaths during regular influenza 
seasons has ranged from 34 deaths during the 2011â€“2012 season to 149 deaths during the 2012â€“
2013 season  (1) (5).  However, between 15 April 2009 and 02 October 2010 (the period of the 
2009 H1N1 influenza pandemic), 348 deaths attr ibuted to laboratory-confirmed 2009 H1N1 
influenza occurred among childre n aged < 18 years, the majority of whom had 1 or more 
underlying medical conditions previously associated  with conferring a grea ter risk for influenza 
complications  (1) (5).Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 20 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 21 of 74Based on current understanding, the epidemiology of influenza B is characterized by major 
epidemics every 2â€“4 years. It causes infections in all age groups, incl uding children, young adults, 
and the elderly. While influenza affects all ag e groups, young children remain at increased risk 
for complications and are more likely than the general population to require hospitalization. 
Influenza B has been associated with myal gia, myositis, pneumonia, and leukopenia in  
children  (6) (7) (8). Across all ages, the burden of disease from  influenza B is less than that from 
A/H3N2 but greater than that from A/H1N1. Overall, it is a significant cause of absenteeism, clinic visits, hospita lizations, and deaths (4).
1.1.2 Prevention and Control of Infection 
Currently, the most effective measure for reducing th e impact of influenza is to vaccinate persons 
at risk each year before the onset of the influe nza season, especially persons at high risk for 
influenza-related complications. The Advisory Committee on Immunization Practices (ACIP) of 
the Centers for Disease Control and Prevention (CDC) recommends that all eligible persons 
6 months of age and older receive an nual vaccination against influenza  (9).
Influenza vaccine has been eff ective in reducing influenza-related morbidity and mortality. The 
effectiveness of the influenza vaccine in preven ting or attenuating influe nza illness depends in 
part on the age and immune competence of the vacci ne recipient and on the similarity between the 
virus strains present in the vaccine and those circulating in the community. Most vaccinated 
children and young adults develop high post-va ccination hemagglutinat ion inhibition (HAI)
antibody titers. These antibodies are protective against illness caused by strains similar to those in 
the vaccine or the related variants that  may emerge during outbreak periods.  
1.1.3 Advisory Committee on Immunization Practices Recommendations
Because children 6 through 23 months of age are at substantially increased risk for influenza-
related hospitalizations, and children 24 through 59 months of age are at increased risk for 
influenza-related clinic and emergency depa rtment visits, ACIP has recommended annual 
vaccination of all eligible child ren in these age groups. In recent years, ACIP has further 
expanded the targeted age groups, and now recommends that all elig ible people 6 months of age 
and older receive annual influenza vaccination (1) (9).  The ACIP continues to emphasize the 
LPSRUWDQFHRIYDFFLQDWLQJSHUVRQVÂ•PRQWKVRIDJHZKRKDYHKL JK-risk medical conditions (1).
If a child 6 months through 8 years of age is receiving influenza vaccine for the first time, based 
on ACIP recommendations, 2 doses of influen za vaccine should be administered during the 
current season. This recommendation is based on st udies demonstrating that vaccine effectiveness 
is lower among children who have never received in fluenza vaccine previously or who received 
only 1 dose in their first year of  vaccination than it is among ch ildren who received 2 doses in 
their first year of being vaccinated. Children 6 mo nths through 8 years of age who are adequately 
primed, based on influenza vaccination history, s hould receive 1 dose during the current season as 
per ACIP recommendations  (1) (9).Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 21 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 22 of 741.2 Background of the Investigational Product
Vaccine Testing and Release
Before being released for clinical use, th e 2016â€“2017 formulation of Fluzone Quadrivalent 
vaccine will have passed all approve d release-testing requirements. 
Previous Clinical Experience Fluzone vaccine was licensed in the United States  in 1947 as a whole-viru s preparation and it has 
been available since 1980 as a split -virus preparation. Numerous clinical trials have demonstrated 
its safety, immunogenicity, and effec tiveness. Clinical trials, in which Fluzone vaccine was used 
as a comparator, have also demonstrated the sa fety and immunogenicity of Fluzone Quadrivalent 
vaccine.  Fluzone Quadrivalent vaccine was firs t licensed in the United States by the Food and 
Drug Administration (FDA) on 07 June 2013 in STN: BL103914/5574 for use in persons 
6 months of age and older.  
1.3 Potential Benefits and Risks
1.3.1 Potential Benefits to Subjects
The benefit to children particip ating in this trial is the re ceipt of the 2016â€“2017 formulation of 
Fluzone Quadrivalent vaccine.
1.3.2 Potential Risks to Subjects
The most frequent side effect of influenza vaccin ation is pain or tenderness at the injection site 
that usually resolves within 3 days. Inj ection site reactions are generally mild. 
Systemic findings such as crying, irritability, or fever (young children); malaise or myalgia (older 
children); and other systemic symptoms can occur following vaccination and most often affect persons who have had no prior exposure to the vaccine antig ens (e.g., young children) (10). These 
reactions usually begin 6 to 12 hours after vaccination and usually resolve within 3 days. A previous trial of children 6 to 36 months of ag e has been published and demonstrates the safety of 
influenza vaccination in this age group  (11).
Immediate allergic reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) 
occur rarely after influenza v accination. These reactions probab ly result from hypersensitivity to 
some vaccine component; the majority is mo st likely related to residual egg protein  (1).
Guillain-BarrÃ© syndrome (GBS) is  a very rare, acute, and frequently severe polyneuropathy 
characterized by ascending fulminant muscle pa ralysis. The 1976 swin e influenza vaccine 
was associated with an increased frequency of GBS. Among persons who received the swine 
influenza vaccine in 1976, the rate of GBS that exceeded the background rate was 
< 10 cases/1,000,000 persons vaccinated. Evidence for a causal relationship of GBS with subsequent vaccines prepared from other in fluenza viruses is unclear. Obtaining strong 
epidemiologic evidence for such a possible limited increase in risk is difficult for a condition as 
rare as GBS, which has an annual incidence of  10â€“20 cases per 1,000,000 adults and stretches the 
limits of epidemiologic investigation. Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 22 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 23 of 74The reasons why swine influenza vaccine triggered GBS in 1976 to 1977 have never been 
discovered. In subsequent annual influenza vaccine  programs in the United States, from 1977 to 
1991, the overall relative ri sk estimates for GBS after influenza vaccination were slightly elevated 
but were not statistically signi ficant in any of the studies. Ho wever, in a study of the 1992â€“1993 
and 1993â€“1994 seasons, the overall relative risk for GBS was 1.7 (95% confidence interval [CI]:
1.0â€“2.8; P=0.04) during the 6 weeks after vaccina tion, representing approximately 1 additional 
case of GBS for each 1,000,000 persons vaccinated. The combined number of GBS cases peaked 
2 weeks after vaccination. A meta-analysis provided a similar risk estimate for GBS following receipt of 2009 influenza A (H1N1) monova lent inactivated influenza vaccine  (12). Thus, 
investigations to date indicate that there is no substantial in crease in GBS associated with 
influenza vaccines (other than the swine influen za vaccine in 1976) and that , if influenza vaccine 
does pose a risk, it is probably slightly more than 1 additiona l case per 1,000,000 persons 
vaccinated. Even if GBS were a true side eff ect of vaccination in the years after 1976, the 
estimated risk for GBS (approximately 1 a dditional case/1,000,000 persons vaccinated) is 
substantially less than the risk for severe influen za, which could be prevented by vaccination in all 
age grouSVDQGHVSHFLDOO\LQSHUVRQVDJH GÂ•\HDUVDQGWKRVHZKRKDYH PHGLFDOLQGLFDWLRQVIRU
influenza vaccination. 
Neurological disorders temporally  associated with influenza vaccination such as myelitis 
(including encephalomyelitis and transverse myelit is), optic neuritis/neuropathy, partial facial 
paralysis, and brachial neuritis have been re ported. However, no cause and effect has been 
established. Almost all persons affected were adul ts, and the described clin ical reactions began as 
soon as a few hours and as late as 2 weeks afte r vaccination. Full recovery was almost always 
reported.In a study of the 2010â€“2011 influenza season, the CD C found that there was a risk of fever-
associated seizure (convulsion) occurring on the day of influenza vaccination and for 1 day after 
vaccination in children 6 months through 4 years of age. The risk was higher among children who 
received concomitant inactivated influenza vaccine and 13-valent pneumococcal conjugate 
vaccine and peaked at approximately age 16 months . The magnitude of the increased risk was less 
than 1 episode per 1,000 children immunize d. A similar risk wa s found during the 2011â€“2012 
season (in which the formulation of the influenza vaccine used was the same as that used during the 2010â€“11 season); however, an increased risk for febrile se izures following influenza 
vaccination was not observed during the 2012â€“13 in fluenza season. No increased risk was found 
for children older than 4 years of  age. After taking into consid eration benefits and risks of 
vaccination, no policy change was recommended for use of inactivated influenza vaccine or 
13-valent pneumococcal conjugate vaccine (1).
There may be other risks not yet identified. 
Please refer to the US Prescribing Information for other adverse events (AEs).
1.4 Rationale for the Trial
The ACIP recommends that children 6 through 35 months of age receive influenza vaccine with 
7.5ÈJHA of each influenza viral strain, in a volume of 0.25 mL compared to 15 ÈJ HA per strain 
in a 0.5-mL dose administered to persons 3 years of  age and older. This recommendation is based 
primarily on the results of la rge multicenter trials of monovale nt and bivalent whole-virus Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 23 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 24 of 74influenza vaccines conducted in children during the 1970s  (13). These studies demonstrated that 
adverse reactions (ARs) were problematic in ch ildren administered whole-virus vaccines and 
downward adjustment of the dose r esulted in improved to lerability. However, the introduction of 
split-virus and subvirion influenza vaccines, which are less reactogenic than whole-virus vaccines, 
may have eliminated the necessity for dose adjustments in this young age group.  
The dose administered to young children may impact the level of protecti on provided by influenza 
vaccines. Clinical studies have shown that va ccine effectiveness may be lower in very young 
children compared with older children. A recen t large randomized trial compared rates of
laboratory-confirmed influenza among 4707 childre n aged 6 through 71 months who received 
inactivated vaccine, MF59-adjuvanted inactivat ed vaccine, or a non-influenza control vaccine
(14).  All study participants received 2 doses 28 days apart: children 6 th rough 35 months of age 
received 0.25 mL per dose and children 36 thr ough 71 months of age received 0.5 mL per dose. 
During the 2 seasons of this study (2007â€“2008 a nd 2008â€“2009), overall efficacy across all age 
groups of non-adjuvanted inactivated vaccine vers us control vaccine agai nst all strains was 43% 
(95% CI: 15%â€“61%) (14).  By age group, efficacy rates were  11% (95% CI: -89%â€“58%) among 
children 6 through 23 months of age, 40% (95% CI: -6%â€“66%) among those 6 through 35 months 
of age, and 45% (95% CI: 6%â€“68%) among those 36 through 71 months of age.  
A 2012 systematic review of published studies estimated vaccine effectiveness among healthy 
children was 40% (95% CI: 6%â€“61%) for those aged 6 through 23 months and 60% (95% CI:
30%â€“78%) for those aged 24 through 59 months  (15). During the 2010â€“2011 season, when all 
3 vaccine virus strains appeared an tigenically similar to circulati ng strains, vaccine effectiveness 
was assessed among children in a large multi-site observational study (16). Vaccine effectiveness 
among children aged 6 months through 2 years was 58% (95% CI: 31%â€“74%) and the 
effectiveness among children aged 3 th rough 8 years was 69% (95% CI: 56%â€“77%).
To evaluate whether a higher dose might induce a more robust antibody response (and potentially 
offer improved protection) among children 6 thro ugh 35 months of age, investigators have 
evaluated the safety and imm unogenicity of a full dose (15 ÈJ HA per strain in 0.5-mL volume)
versus a half dose (7.5 ÈJHA per strain in 0.25-mL volume). 
Skowronski and colleagues evaluated 252 previo usly unimmunized children 6 through 23 months
of age who were randomly assigned to receive 2 doses administered 4 to 6 weeks apart of full-
dose (15ÈJHA per strain) or half-dose (7.5 ÈJHA per strain) trivalent inactivated influenza 
vaccine (IIV3) during the 2008â€“2009 season  (17). Children administered full-dose IIV3 
responded with higher geometric mean HAI antib ody titers to all 3 vaccine  components compared 
to those who received half-dose IIV3. In addi tion, seroprotection and se roconversion rates were 
higher among children 6 through 11 months of ag e who received the full-dose vaccine. For 
example, seroprotection rates ranged between 40 % and 55% in the half -dose group and between 
70% and 75% in the full-dose group. Rates of fe ver were not higher among full- versus half-dose 
recipients. Rates of injection site reactions were lower in the half-dose group, but the differences between groups were not statistically significant. 
Esposito and colleagues investigated full-dose (15 ÈJHA per strain) versus half-dose (7.5 ÈJHA
per strain) virosoma 
l-adjuvanted  subunit IIV3 (2008â€“2009 season) administered 4 weeks apart to 
65 previously unvaccinated children 6 through 35 months of age  (18). Following the first dose, 
HAI titers were significantly higher in the full-dose group compared with the half-dose group for Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 24 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 25 of 74all 3 antigens. No significant differences in HAI titers between groups were noted 4 weeks after 
the second administration, but HAI titers were significantly higher among the full-dose recipients 
6 months post-vaccination for 2 of the strains (H1N1 and H3N2). There was no increase in 
systemic or injection site reactions in the full-dose group versus the half-dose group. A
subsequent Phase III study conducted by these same investigators during the 2010â€“2011 season 
further supported that a single 0.5-mL dose of the virosomal-adj uvanted subunit influenza vaccine 
could effectively and safely provide long-term immunogenicity to all 3 influenza strains in 
unprimed children 6 through 35 months of age  (19).
Langley and colleagues studied 374 children 6 through 35 months of age who were randomly 
assigned 1:1 to receive either a full-dose (15 ÈJHA per strain) or half-dose (7.5 ÈJHA per strain) 
of IIV3 during the 2008â€“2009 season  (20). One or 2 doses were administered to primed and 
unprimed children, respectively. Geometric mean  HAI antibody titers and seroprotection and 
seroconversion rates were higher among children 6 through 23 months  of age who received full-
dose IIV3 versus half-dose IIV3, although the differen ces were not statistically significant. In 
general, differences of these endpoints between the full- and half-dose groups were greater for the 
younger children 6 through 23 months of age compar ed to the older cohort  24 through 35 months 
of age. There were no statistic ally significant differences in reactogenicity between the 2 dose
groups. Fever was not reported more frequently in children who received the full-dose IIV3 
versus those who received the half-dose IIV3. 
Finally, Halasa and colleagues enrolled 243 child ren 6 through 35 months of age during the 2010â€“
2011 and 2011â€“2012 seasons and randomly assigned them 2:1 to receive either full-dose (15 ÈJ
HA per strain) or half-dose (7.5 ÈJHA per strain) IIV3 (1 or 2 doses depending on vaccination 
history)  (13). Among primed subjects, the geometric mean HAI antibody response to H1N1 was 
significantly higher in th e full-dose group. A similar higher response to H1N1 in the full-dose 
versus half-dose group was observed among naÃ¯ve s ubjects 12 through 35 months of age, although 
the difference was not statistica lly significant. No immunologic di fferences between groups were 
noted for the other antigens in the primed or na Ã¯ve cohorts. No significant differences between the 
full- and half-dose groups were observed for sy stemic and injection site reactions among the 
primed and naÃ¯ve cohorts for the 2 seasons combined.  In summary, vaccine efficacy and effectivene ss studies have generally demonstrated that 
inactivated influenza vaccines reduce influenza disease in children, but in some studies the 
effectiveness in children 6 through 35 months of age is lower than that in children 3 years of age 
and older. The practice of ad ministering half-dose IIV (7.5 ÈJHA per strain; 0.25 mL) to young 
children originates from experience with whole-virus vaccin e, which was reactogenic and 
frequently caused fever in young children. Split- virus and subvirion influenza vaccines are less 
reactogenic and data from the studies cited above support the safety of the full-dose IIV (15 ÈJ
HA per strain; 0.5-mL dose) in this population. Furthe r, data from recent studies suggest that in 
children 6 through 35 months of age, full-dose influenza vaccine induces generally higher 
antibody responses compared to those induced by  half-dose vaccine, without causing materially
higher rates of systemic or in jection site reactions. In most studies, differences in antibody 
responses between the full- and half-dose groups were greatest in the youngest age cohorts 
(i.e., 6- through 11-month-old or 6- through 23-month-old children). 
Full-dose influenza vaccine is now recommende d for all children, including those 6 through 
35
months of age, by health authorities in Canada  (21), the United Kingdom, and Finland (13). In Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 25 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 26 of 742012, when the Canadian National Advisory  Committee on Immunization (NACI) first 
recommended a full 0.5-mL dose for childre n 6 through 35 months of age, it stated  (22):
â€œInfants and toddlers have a high burden of illness and their re sponse to [IIV3] is 
not as robust as with older children. Published and unpublished evidence suggests 
moderate improvement in antibody response in infants, without an increase in 
reactogenicity, with the use of full vaccine  doses. In light of this evidence, NACI 
recommends that children 6 to 35 mont hs of age should be given a full dose 
(0.5 mL) of [IIV3] instead of the previously recomme nded half dose (0.25 mL). 
This recommendation applies whether the ch ild is being given one dose of [IIV3]
or a two dose series.â€ 
Moreover, although influenza vaccine coverage  among young children continues to improve, 
coverage is not yet at desi red levels. During the 2013â€“2014 seas on, 70.4% of children 6 months 
through 4 years of age received at least 1 dose of an influenza vaccine  (23).  However, coverage 
rates with 2 doses of influenza vaccine ar e far lower. During th e 2011â€“2012 season, 59.2% and 
40.5% of children 6 through 23 months and 24 through 59 months of age, respectively, received at 
least 1 dose of influenza vaccine, but only 42.9% and 29.0% of children in the same age cohorts 
were fully vaccinated  (24). Similarly, during the 2012â€“2013 s eason, 65.9% and 45.9% of children 
6 through 23 months and 24 through 59 months of ag e, respectively, received at least 1 dose of 
influenza vaccine, but only 45.5% and 31.4% to 33.6% (depending on the definition of unprimed 
children for whom 2 doses were recommended) of childre n in the same age cohorts were fully 
vaccinated  (25). Ferdinands and colleagues recently unde rscored the importance of being fully 
vaccinated by demonstrating that such children were 74% (95% CI: 19%â€“91%) or 82% (95% CI: 
23%â€“96%) less likely to be admitted to a pediatri c intensive care unit (PICU) for influenza 
compared to PICU controls or community contro ls, respectively. In stark contrast, receipt of 
1 dose of vaccine among children for whom 2 doses were recommende d was not protective  (26).Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 26 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 27 of 74Based on the foregoing, there is a strong rationa le to allow use of the 0.5-mL dose for young
children. Consequently, the purpose of the study desc ribed herein is to describe the safety and 
immunogenicity of the 0.5-mL dose (15 ÈJHA per strain) of Fluzone Quadrivalent vaccine in 
children 6 through 35 months of age, with the intent to modify the vaccineâ€™s Prescribing 
Information (Dosage and Administration) to show the 0.5-mL dose of Fluzone Quadrivalent 
vaccine as indicated for all ages 6 months and older, including children 6 months through 8 years 
of age (who might receive 1 or 2 doses as recommended by the ACIP). 
2 Trial Objectives
2.1 Primary Objective
To compare the rate of any fever (temperature Â•ÂƒF [38.0Â°C]) following the 0.5-mL dose of 
Fluzone Quadrivalent vaccine to that follo wing the 0.25-mL dose of Fluzone Quadrivalent 
vaccine during the 7 days after either vaccinati on (Dose 1 and Dose 2 combined) in subjects 
6 to < 36 months of age. 
The endpoints for the primary objective are presented in  Section 9.1.1.1.
2.2 Secondary Objective
To compare antibody responses induced by the 0.5- mL dose of Fluzone Quadrivalent vaccine to 
those induced by the 0.25-mL dose of Fluzone Qu adrivalent vaccine as assessed by geometric 
mean titer (GMT) ratios and seroconversion rate diffe rences after the final vaccination in subjects 
6 to < 36 months of age. The endpoints for the secondary objective are presented in  Section 9.2.2.1.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 27 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 28 of 742.3 Observational Objectives
2.3.1 Safety
To describe the safety of 2 different dose levels of th e 2016â€“2017 formulation of Fluzone 
Quadrivalent vaccine in subjects  6 to < 36 months of age.  
The endpoints for the observational safety objective are presented in  Section 9.3.1.2.
2.3.2 ImmunogenicityTo describe the immunogenicity of 2 differe nt dose levels of the 2016â€“2017 formulation of 
Fluzone Quadrivalent vaccine in subjects 6 to < 36 months of age.  
The endpoints for the observational imm unogenicity objective are presented in Section 9.3.2.1.
2.3.3 Serum Collection
There are no endpoints for the serum collection objective. 
3 Investigators and Trial Organization
This trial will be conducted in approximately 38 centers in the United States . Details of the trial 
centers, the Investigators at each center, and the Coordinating Inve stigator(s) are provided in the 
â€œList of Investigators and Centers Involved in the Trialâ€ document. 
The Sponsorâ€™s Responsible Medical Officers (RMOs) (t he persons authorized to  sign this protocol 
and any amendments on behalf of the Sponsor) are 
or such delegate(s) as may be identified in their absence.
4 Institutional Review Board
Before the investigational product can be shippe d to the investigationa l site and before the 
inclusion of the first subject, this protocol, the informed c onsent form(s) (ICF[s]), subject 
recruitment procedures, and any ot her written information to be provided to subjects must be 
approved by, and/or receive favor able opinion from, the appropriate  Institutional Review Board(s) 
(IRB[s]).
In accordance with Good Clinical Practice (GCP) and local regulations, each Investigator and/or 
the Sponsor are responsible for obt aining this approval and/or favorable opinion before the start of 
the trial. If the protocol is subsequently amended, approval must be re-obtained for each 
substantial amendment. Copies of these approvals, along with information on the type, version number, and date of document, and the date of a pproval, must be forwarded by the Investigator to Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 28 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 29 of 74the Sponsor together with the composition of the IRB(s) (the names and qualifications of the 
members attending and voting at the meetings).
The Investigator will submit written summaries of the status of the trial to the IRB(s) annually, or 
more frequently if requested. All serious adverse events (SAEs) occurring during the trial that are 
related to vaccination will be repor ted by the Investigator to the IRB(s), according to IRB policy. 
5 Investigational Plan
5.1 Description of the Overall Trial Design and Plan
5.1.1 Trial Design
This will be a Phase IV, randomized, observer-bli nded, 2-arm, multi-center trial to evaluate the 
safety and immunogenicity of 2 different dose le vels of Fluzone Quadrivalent vaccine in 
approximately 2190 healthy children 6 to < 36 months of age.
5.1.2 Justification of the Trial Design
See Section 1.4 for the justification for the selection of subjects. The trial will be conducted in a
modified double-blind (i.e., observer- blinded) fashion, with both th e Investigators and the subjects
unaware of which vaccine is being administered, to secure objective collection and assessment of 
safety data.
5.1.3 Trial Plan
Using a pre-programmed interactive response technology (IRT) system, subjects will be randomly 
assigned in a 1:1 ratio to eith er 1 of the following groups:
xGroup 1: 0.25 mL of Fluzone Quadrivalent  vaccine (approximately 1095 subjects)
xGroup 2: 0.5 mL of Fluzone Quadrivalent  vaccine (approximately 1095 subjects) 
Enrollment will be stratified by age at each site so that approximately 50% of subjects at each site 
will be 6 to < 24 months of age and approximately 50% of subjects at each site will be 24 months to < 36 months of age. If necessary to achieve 50% overall enrollment of subjects 6 to < 24 
months of age, individual sites may be permitted to deviate from this ratio. 
All subjects will receive 1 in tramuscular dose of Fluzone Quadrivalent vaccine (0.25 mL 
[Group 1] or 0.5 mL [Group 2]) during Visit 1. Fo r subjects for whom 2 doses of influenza 
vaccine are recommended per ACIP guidance, a second dose of Fluzone Quadrivalent vaccine 
(same 0.25-mL or 0.5-mL dose as administered at Visit 1) will be administered during Visit 2 
(28 [window, 28â€“35] days after Visit 1). Blood specimens will be obtained from a planned s ubset of 1600 subjects randomly selected by an 
IRT system (half in Group 1 and half in Group 2) prior to the first vacc ination and 28 (window, 
28â€“35) days following the final vaccination (Visit 2 for subjects receiving 1 dose; Visit 3 for 
subjects receiving 2 doses) a nd assayed for immunogenicity.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 29 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 30 of 74Solicited AE information will be collected for 7 days after each vaccination. Unsolicited AE 
information and SAE information will be collected from Visit 1 to Visit 2 for subjects receiving 1 
dose or from Visit 1 to Visit 3 for subjects receiving 2 doses. 
Note: Any SAE that occurs after a subject has comp leted the study but that is  likely to be related 
to the product is to also be reported to the Sponsor. 
5.1.4 Visit Procedures
All subjects, Investigators and study site staff, and Sponsor personnel involved in the clinical trial 
will be blinded to the vaccine administered, with the exception of unblinded qualified study staff 
who will administer the vaccine. The unblinded qua lified study staff will not participate in the 
collection of safety data.
Medical procedures (injections, ex aminations, etc.) must be conducted by appropriately licensed 
or credentialed study site st aff working within the scope of their licenses/credentials.
Visit 1 (Day 0): Inclusion and Vaccination
The Investigator or delegate will:
1)Explain the trial, including but not limited to  its objectives and design and the potential risks 
and benefits of participating, to  the subjectâ€™s parent/guardian, and answer any questions the 
subject or subjectâ€™s pa rent/guardian may have.
2)Obtain a written informed consent from the s ubjectâ€™s parent/guardian. The Investigator or 
delegate will also sign and date the ICF, retain  the original, and give a copy of the signed and 
dated form to the subjectâ€™s parent/guardian.
3)Check eligibility of the subjec t by reviewing appli cable inclusion and exclusion criteria.
4)Collect relevant demographic information (d ate of birth, sex, race, and ethnic origin).
5)Obtain significant medical history (see  Section 5.2.6 for details).
6)Collect influenza vaccination history to determine vaccination schedule (1 dose versus 
2 doses) per ACIP recommendations  in effect during the study. 
7)Perform a directed physical examination, if indicated, based on medical history.
8)Measure the temperature by the pr eferred route (i.e., rectal; see  Section 9.3.1.3.2) and record 
this information in the source document. If the subject has a WHPSHUDWXUHÂ• 100.4Â°F 
(Â• 38.0oC) defer enrollment until the subject has been afebrile for at least 24 hours (see
Section 5.2.7.1) .
9)If subject meets all inclusion and no exclusion criteria, conn ect to the IRT system to enter 
required data to receive subject number and vaccine dose identifica tion number, and to 
determine if subject has been assi gned to the immunogenicity subset.
10)If subject is randomly assigned to the imm unogenicity subset, obtain a pre-vaccination blood 
sample (approximately 5 mL; see Section 7.1 for detailed instructions regarding the collection 
of blood samples).
The unblinded qualified study staff member will:Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 30 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 31 of 7411)Prepare the study product according to the group assignment and based on the information 
provided in Section 6.1.1.2.
12)Within 30 minutes of removing the assigned vaccin e from the refrigerator, inject 1 dose of 
Fluzone Quadrivalent vaccine (0.25 mL [Group 1] or 0.5 mL [Group 2]) intramuscularly into 
the anterolateral muscle of the thigh or the deltoid muscle, as appropriate.
The Investigator or delegate will:
13)Observe subject for 20 minutes following the in jection for the occurrence of allergic and 
anaphylactic reactions and immediate in jection site and systemic reactions.
14)Provide Diary Card 1 to the subjectâ€™s parent/ guardian to record solicited injection site and 
systemic reactions from Day 0 to Day 7 post- vaccination, and unsolicited AEs, SAEs, as well 
as any concomitant medications (see  Section 6.7) from Visit 1 to Visit 2.
15)Provide the subjectâ€™s parent/gua rdian with a digital thermometer and flexible ruler along with 
instructions for their use.
16)Schedule Visit 2. Remind the subjectâ€™s parent/gua rdian that they will be contacted by phone 
on or about Day 8 post-vaccination to remind them  to complete the diary card and to bring 
the completed diary card with them to Visit 2.
17)Remind the subjectâ€™s parent/guardian to notify the site immediately if an SAE occurs.
18)Complete the relevant electronic case report form (eCRF) pages for this visit.
Telephone Contact â€“ Visit 1 + 8 (window, 8â€“10) days
Eight days after the study vaccination at Visit 1, a delegated staff member from the study site will 
telephone the subjectâ€™s parent/gua rdian to perform the following:
1)Remind the subjectâ€™s parent/guardian to reco rd on the diary card any AEs and any 
concomitant medications (see Section 6.7)  from Visit 1 until Visit 2.
2)Remind the subjectâ€™s parent/guardian to notify th e site immediately if an SAE occurs. If an 
SAE occurs, follow the instructions in  Section 10 for reporting it.
3)Confirm the date of the appointment of Visit 2, in struct the subjectâ€™s pare nt/guardian to return 
at this time, and to bring the complete d diary card with them to the study site.
Note:  If Day 8 falls on a weekend or a holiday, the telephone call may be placed preferably on the 
following business day. If the subjectâ€™s parent/gua rdian is not available,  the study staff should 
document the attempts to make contact.
Visit 2 (Visit 1 + 28 [window, 28â€“35] days) â€“ Subject s Receiving 1 Dose of Influenza Vaccine -
Collection of Safety Information and Blood Sample 
The Investigator or delegate will:
1)Review Diary Card 1 with the subjectâ€™s paren t/guardian for accuracy and collect it as the 
source document.
2)Review interim health history, in cluding any AEs, medications, or  therapy that occurred since 
vaccination.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 31 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 32 of 743)If subject is part of the immunogenicity subset, obtain blood  sample (approximately 5 mL; 
see Section 7.1 for detailed instructions regarding the collection of blood samples). 
4)Complete the relevant eCRF pages for this visit as well as the termination record in the eCRF.
Visit 2 (Visit 1 + 28 [window, 28â€“35] days) â€“ Subj ects Receiving 2 Doses of Influenza Vaccinea
- Second Vaccination and Collection of Safety Information  
The Investigator or delegate will:
1)Review Diary Card 1 with the subjectâ€™s paren t/guardian for accuracy and collect it as the 
source document.
2)Review interim health history, in cluding any AEs, medications, or  therapy that occurred since 
vaccination.
3)Perform a history-directed physical examination. 
4)Measure the temperature by the pr eferred route (i.e., rectal; see  Section 9.3.1.3.2) and record 
this information in the source document. If the subject has a WHPSHUDWXUHÂ• 100.4Â°F 
(Â• 38.0oC) defer enrollment until the subject has been afebrile for at least 24 hours (see
Section 5.2.7.1) .
5)Contact the IRT system to have vaccine  dose identification number assigned.
The unblinded qualified study staff member will:
6)Prepare the study product according to the information provided in  Section 6.1.1.2.
7)Within 30 minutes of removing the vaccine from the refrigerator, inject subject with the same 
dose of vaccine administered to  the subject during Visit 1 (i .e., either 0.25 mL or 0.5 mL) 
intramuscularly into the anterolateral muscle of the thigh or the deltoid muscle, as 
appropriate.
The Investigator or delegate will:
8)Observe subject for 20 minutes following the inj ection for the occurrence of allergic and 
anaphylactic reactions and immediate injection site and systemic reactions.
9)Provide Diary Card 2 to the subjectâ€™s parent/ guardian to record solicited injection site and 
systemic reactions from Day 0 to Day 7 post- vaccination, and unsolicited AEs, SAEs, as well 
as any concomitant medications (see  Section 6.7) from Visit 2 to Visit 3.
10)Schedule Visit 3. Remind the subjectâ€™s parent/gua rdian that they will be contacted by phone 
on or about Day 8 post-vaccination to remind them  to complete the diary card and to bring 
the completed diary card with them to Visit 3.
11)Remind the subjectâ€™s parent/guardian to notify the site immediately if an SAE occurs.
12)Complete the relevant eCRF pages for this visit.
aAs per ACIP guidance.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 32 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 33 of 74Telephone Contact â€“ Visit 2 + 8 (window, 8â€“10) days
Eight days after the study vaccination at Visit 2 (for subjects receiving a second vaccination), a 
delegated staff member from the study site will telephone the subjectâ€™s parent/guardian to perform 
the following:
1)Remind the subjectâ€™s parent/guardian to record on the diary card any AEs and any 
concomitant medications (see Section 6.7)  from Visit 2 until st udy termination Visit 3.
2)Remind the subjectâ€™s parent/guardian to notify th e site immediately if an SAE occurs. If an 
SAE occurs, follow the instructions in  Section 10 for reporting it.
3)Confirm the date of the appointment of Visit 3. In struct the subjectâ€™s pare nt/guardian to return 
at this time and to bring the complete d diary card with them to the study site.
Note: If Day 8 falls on a weekend or a holiday, the telephone call may be placed preferably on the 
following business day. If the subjectâ€™s parent/gua rdian is not available,  the study staff should 
document the attempts to make contact.
Visit 3 (Visit 2 + 28 [window, 28â€“35] days) â€“ Subjects Receiving 2 Doses of Influenza Vaccinea-
Collection of Safety Information and Blood Sample 
The Investigator or delegate will:
1)Review Diary Card 2 with the subjectâ€™s paren t/guardian for accuracy and collect it as the 
source document.
2)Review interim health history, in cluding any AEs, medications, or  therapy that occurred since 
vaccination.
3)If subject is part of the immunogenicity subset, obtain blood  sample (approximately 5 mL; 
see Section 7.1 for detailed instructions regarding the collection of blood samples). 
4)Complete the relevant eCRF pages for this visit as well as the termination record in the eCRF.
Collection of Diary Cards  If the subjectâ€™s parent/guardian do es not return for Visit 2 or Vi sit 3, and the diary card is not 
received at the site, site pers onnel will contact the subjectâ€™s parent/guardian by telephone. During 
the telephone call, the subjectâ€™s pa rent/guardian will be reminded to return the diary card to the 
study site. Telephone calls will be recorded in the subjectâ€™s source documents. If study personnel 
are unable to contact the subject's parent/guardian by telephone with 3 attempts, study personnel 
will follow instructions given in  Section 5.2.9.
SAEs and AEs That Are Related to Vacci nation or That Led to Discontinuation:
At any time during the study, a subject who experien ces an SAE or an AE must be followed if 
either  of the following is true:
xThe SAE or AE is considered by the Investigator to be rela ted to vaccination and is not 
resolved by the end of the subjectâ€™s participation in the trial
aAs per ACIP guidanceSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 33 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 34 of 74xThe subject has been discontinued from the trial because of the SAE or AE
Any such subject must be followed until the condition resolves, becomes stable, or becomes 
chronic, unless the subjectâ€™s pare nt/guardian specified that they do not want to be contacted for 
follow-up and it is documented in the source document.
5.1.5 Planned Trial Calendar
The following dates are approximate. The actual date s may differ as, for example, the trial will 
not start until all the appropriate regulatory  and ethical approval s have been obtained.
Planned trial period - FVFS (first visit, first subject) to LVLS (last visit, last subject):
September 2016 to February 2017
Planned end of trial: February 2017Planned date of final clinical  study report: within approximately  10 months of study completion.
5.1.6 Early Safety Data Review
This trial will not include an early review of sa fety data. However, it may be interrupted at any 
time if new data about the inve stigational product become availa ble, and/or on advice of the 
Sponsor, the IRB(s), or the FDA.
If the trial is prematurely terminated or su spended, the Sponsor will promptly inform the 
Investigators, the IRB(s), and the FDA of the reas on for termination or susp ension. If the trial is 
prematurely terminated for any reason, the Investigator will promptly inform the trial subjectsâ€™ 
parents/guardians and should a ssure appropriate therapy fo r and follow-up of subjects.
5.2 Enrollment and Retent ion of Trial Population
5.2.1 Recruitment Procedures
Subjects may be recruited from the general population. The site will ensure that any 
advertisements used to recruit s ubjects (informational brochures, pa rent letters, posters, and other 
advertisements) are submitted to Sanofi Pasteur prior to submission to the IRB for approval.
5.2.2 Informed Consent Procedures
Informed consent is the process by which a subj ectâ€™s parent/guardian voluntarily confirms his or 
her willingness to participate in a particular tria l. Informed consent must be obtained before any 
study procedures are performed. The process is documented by means of a written, signed, and 
dated ICF.
In accordance with GCP, prior to signing and dating  the consent form, the subjectâ€™s parent/guardian
must be informed by appropriate study personnel about  all aspects of the trial that are relevant to 
making the decision to participate, and must ha ve sufficient time and opportunity to ask any 
questions.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 34 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 35 of 74The actual ICF used at each center may di ffer, depending on local regulations and IRB 
requirements. However, all versions must contai n the standard information found in the sample 
ICF provided by the Sponsor. Any change to the content of the ICF must be approved by the 
Sponsor and the IRB prior to the form being used. 
If new information becomes available that may be  relevant to the subject â€™s parentâ€™s/guardianâ€™s 
willingness to continue participation in the trial,  this will be communicated to him/her in a timely 
manner. Such information will be provided via a re vised ICF or an addendum to the original ICF. 
Informed consent forms will be provided in dupli cate, or a photocopy of the signed consent will 
be made. The original will be kept by the Inves tigator, and the copy will be kept by the subjectâ€™s
parent/guardian.Documentation of the consen t process is to be recorded in the source documents.
5.2.3 Screening Criteria
There are no screening criteria other than  the inclusion and exclusion criteria.
5.2.4 Inclusion CriteriaAn individual must fulfill allof the following criteria in order to be eligible for trial enrollment:
1)Aged 6 to < 36 months of age on the day of first study vaccination (study product 
administration).a
2)Born at full term of pregnancy (Â• 37 weeks) and/or with a birth weight Â•2.5 kg.
Note: This inclusion criterion only applies to subj ects 6 to < 12 months of age on the day of 
the first study visit.
3)Informed consent form has been signed and dated by the parent(s) or guardian(s).
4)Subject and parent/guardian are ab le to attend all scheduled visits  and to comply with all trial 
procedures.
5.2.5 Exclusion Criteria
An individual fulfilling anyof the following criteria is to be excluded from trial enrollment:
1)Participation at the time of study enrollment (or in the 30 days preceding the first trial 
vaccination) or planned participation during the present trial period in another clinical trial 
investigating a vaccine, drug, medical  device, or medical procedure. 
Note:  Subjects may be considered eligible for enrollment if no intervention for the other 
study occurred within the 30 days prior to th e first study vaccination and none are planned 
before the subject would complete safe ty surveillance for the present study. 
aâ€œ6 to < 36 monthsâ€ means from the first day of the 6th month after birth to the day before the 36th monthSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 35 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 36 of 742)Receipt of any vaccine in the 30 days preceding the first trial vaccination, or planned receipt 
of any vaccine before Visit 2 for subjects receiv ing 1 dose of influenza vaccine or Visit 3 for 
subjects receiving 2 doses of influenza vaccine.
3)Previous vaccination against inf luenza (in the 2016â€“2017 season) with  either the trial vaccine 
or another vaccine.
4)Receipt of immune globulins, blood, or bl ood-derived products in the past 3 months.
5)Known or suspected congenital or acqui red immunodeficiency ; or receipt of 
immunosuppressive therapy, such as anti-cance r chemotherapy or radiation therapy, within 
the preceding 6 months; or l ong-term systemic corticosteroid therapy (prednisone or 
equivalent for more than 2 consecutive weeks within the past 3 months).
6)Known systemic hypersensitivity to any of th e vaccine components, or history of a life-
threatening reaction to the vaccine used in the tr ial or to a vaccine containing any of the same 
substances. 
Note:  The list of vaccine components is include d in the Prescribing Information and in 
Section 6.1.1.1.
7)Thrombocytopenia, which may be a contraindi cation for intramuscula r vaccination, at the 
discretion of the Investigator.
8)Bleeding disorder, or receipt of anticoa gulants in the 3 weeks preceding inclusion, 
contraindicating intram uscular vaccination.
9)Deprived of freedom by an administrative or c ourt order, or in an emergency setting, or 
hospitalized involuntarily.
10)Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere 
with trial conduc t or completion.a
11)Moderate or severe acute illness/infection (acco rding to Investigator judgment) on the day of 
SODQQHGYDFFLQDWLRQRUIHEULOHLOOQHVVWHPSHUDWXUHÂ•  100.4Â°F [38.0oC]). A prospective subject 
should not be included in the study until the co ndition has resolved or the febrile event has 
subsided.
12)Identified as a natural or adopted child of either the Investigat or or an employee with direct 
involvement in the proposed study.
13)History of serious ARs to any influenza vaccine.
14)Personal history of GBS. 
15)Any condition that in the opinion of the Investigator would pose a health risk to the subject if 
enrolled or could interfere with  the evaluation of the vaccine.
16)Personal history of clinically significant de velopmental delay (at the discretion of the 
Investigator), neurologic di sorder, or seizure disorder.
aChronic illness may include, but is not limited to, cardia c disorders, renal disorders, autoimmune disorders, 
diabetes, psychomotor diseases, and known congenital or genetic diseasesSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 36 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 37 of 7417)Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C. 
Note: Subjects enrolled into this study will not be prohibited from donating blood for non-
interventional studie s or other purposes.
5.2.6 Medical History
Prior to enrollment, subjects will be assessed for pre-existing conditions and illnesses, both past 
and ongoing. Any such conditions will be documented in the source document. Significant 
medical history (reported as diagnosis), including conditi ons for which the subject is or has been 
followed by a physician, or conditions that could resume during the course of the study or lead to an SAE or to repetitive outpati ent care will be collected in the eCRF. The significant medical 
history section of the eCRF contains a core list of body systems a nd disorders that could be used 
to prompt comprehensive reporting, as well as sp ace for the reporting of specific conditions and 
illnesses.
For each condition, the data co llected will be limited to:
xDiagnosis (this is preferable to reporting signs and symptoms
a)
xPresence or absence of the condition at enrollment
Dates, medications, and body systems are not to be  recorded, and the information collected will not
be coded. Its purpose is to assist in the later interpretation of safety data collected during the trial.
5.2.7 Contraindications for Subsequent Vaccinations
5.2.7.1 Temporary Contraindications
Should a subject experience 1 of the conditions listed below, the I nvestigator will postpone further 
vaccination until the condition is resolved. Postpone ment must still be wi thin the timeframe for 
vaccination indicated in the Table of Study Procedures .
xFebrile illness (temperature Â• 100.4Â°F [ Â• 38.0Â°C]) or moderate or severe acute 
illness/infection on the day of planned vacci nation, according to Investigator judgment
5.2.7.2 Definitive ContraindicationsShould a subject experience 1 or more of the conditions listed be low after the first dose of study 
vaccine, the Investigator will not administer the se cond dose of vaccine that has been allocated for 
use in the study (i.e., study vaccine); however, th e Investigator may administer a second dose of 
licensed, non-study influenza vaccine in accordance with standard clinical care. 
Definitive contrai ndications include:
xAn anaphylactic or other signifi cant allergic or serious reaction to the previous dose of 
vaccine.
aInvestigators are highly encouraged to evaluate signs and symptoms to establish and report a diagnosis whenever 
feasible; reporting only signs and symptoms in lieu of a unifying diagnosis is strongly discouragedSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 37 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 38 of 74xReceipt of any non-study vaccine (incl uding a non-study dose of 2016â€“2017 influenza 
vaccine), immune globulins, blood, or blood-de rived products between Visit 1 and Visit 2.
xBleeding disorder, receipt of anticoagulant s, or thrombocytopenia, which may be a 
contraindication for intramus cular vaccination, at the disc retion of the Investigator.
xDevelopment of any condition that in the opinion of the Investig ator would pose a health risk
to the subject or could interf ere with the evaluation of the study vaccine (including GBS, 
clinically significant developmental delay, ne urologic disorder, seiz ure disorder, human 
immunodeficiency virus, hepa titis B, or hepatitis C).
xDevelopment of an immunodeficien cy; or receipt of immunosuppres sive therapy such as anti-
cancer chemotherapy or radiation therapy; or receipt of long-term systemic corticosteroid 
therapy (prednisone or equivalent fo r more than 2 consecutive weeks).
xAdverse events that are consider ed a contraindication for further participation in the trial.
xPoor or non-compliance by the subject. In case s where a subject is outside the recommended 
visit schedule, the subject may be continued in the study as a protocol violator and will be 
analyzed accordingly.
Subjects will not be w ithdrawn due to a definitive contraindi cation but will be followed up for 
safety and possibly immunogenicity assessment.
5.2.8 Conditions for Withdrawal
Parents/guardians will be informed that they have  the right to withdraw their child from the trial at 
any time. A subject may be withdrawn from the study for any of the following:
xAt the discretion of the Investig ator or Sponsor due to safety  concerns (withdrawal) without 
the parentâ€™s/guardianâ€™s permission
xAt the request of the parent/guardian (dropout)
The following will result in automatic withdrawal or exclusion of a subject from the study:
xSignificant non-compliance with the protocol , based on the Investigatorâ€™s judgment
The reason for a withdrawal or dropout should be  clearly documented in the source documents 
and on the eCRF. 
The Investigator must determine whether voluntary withdrawal is due to safety concerns (in 
which case, the reason for discon tinuation will be noted as â€œSAEâ€ or â€œother AEâ€ as appropriate) 
or for another reason.
Withdrawn subjects will not be replaced.
5.2.9 Lost to Follow-up Procedures
In the case of subjects who fail to return fo r a follow-up examination, documented reasonable 
effort (i.e., documented telephone calls and certifie d mail) should be undertaken to locate or recall 
them, or at least to determine their health status  while fully respecting their rights. These efforts 
should be documented in the eCRF and in the source documents.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 38 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 39 of 745.2.10 Classification of Subjects Who Discontinue the Trial
For any subject who discontinues the trial prior to completion, th e most significant reason for 
early termination will be checked in the eCRF. Reasons are listed below from the most significant 
to the least significant (refer to the eCRF co mpletion guidelines for additional details and 
examples):
xSerious adverse event: To be used when a subject drops out of or is withdrawn from the 
study by the Investigator because of the occurrence of an SAE, as defined in  Section 9.3.1.1.
xOther adverse event:  To be used when a subject drops out of or is withdrawn from the study 
by the Investigator because of the occurrence of  an AE other than an SAE, as defined in 
Section 9.3.1.1.
xNon-compliance with protocol:  To be used when the Investig ator withdraws a subject from 
the study because of failure to follow protoc ol guidelines, including the case when it is 
retrospectively discovered that a subject did not fulfill the eligibility criteria. The Investigator 
will provide a comment as to the specific cause of non-compliance.
xLost to follow-up:  To be used when the Investigator withdraws a subject from the study 
because of failure to esta blish contact, as outlined in  Section 5.2.9. The Investigator will provide
documentation that contact was attempted (i.e., re turn of unsigned certified letter receipt).
xVoluntary withdrawal not due to an adverse event: To be used when a subject drops out of 
the study for any reason othe r than those listed above. 
5.2.11 Follow-up of Discontinuations
The site should complete all scheduled safety fo llow-ups and contact the parent/guardian of any 
subject who has prematurely terminated the trial  because of an SAE, other type of AE, non-
compliance with the protocol, or loss of elig ibility, including definitive contraindications.
For subjects where the reason for early termination was loss to follow-up or if the subjectâ€™s 
parent/guardian withdrew informed consent and sp ecified that they do not want to be contacted 
again and it is documented in the source document,  the site will not attempt to obtain further 
safety information. 
For subjects where the reason for early termination is voluntary withdrawal, the site will attempt 
to contact the subjectâ€™s parent/ guardian except if they specified that they do not want to be 
contacted again and it is documented in the source document. 
5.3 Safety Emergency Call
If, as per the Investigatorâ€™s judgment, a subject experiences a medical emergency, the Investigator 
may contact the Sponsorâ€™s RMOs for advice on tr ial-related medical questions or problems. The 
RMOs will be available 24 hours a day, 7 days a week, as needed. Contact information for the 
RMOs is provided in the Operating Guidelines.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 39 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 40 of 74Making an emergency call does not replace the need to report an SAE. The Investigator is still 
required to follow the protocol-defined process for reporting SAEs to the Global 
PharmacoVigilance (GPV) Department (Please refer to Section 10) .
5.4 Modification of the Trial and Protocol
Any amendments to this trial plan and protocol  must be discussed with and approved by the 
Sponsor. If agreement is reached  concerning the need for an amendment, it will be produced in 
writing by the Sponsor, and the amended version of the protocol will repl ace the earlier version. 
All substantial amendments (e.g., that affect the conduct of the trial or th e safety of subjects)
require IRB approval and must  also be forwarded to regulatory authorities. 
An administrative amendment to a protocol is one that modifies some admi nistrative or logistical 
aspect of the trial but does not affect its design or objectives or have an impact on the subjectsâ€™ safety. Regulatory authorities need only be notif ied about administrative changes. Administrative 
changes do not require IRB approval; however, the IRB(s) must be notified whenever one is made.
The Investigator is responsible for ensuring that changes to an approved trial, during the period 
for which IRB approval has already been give n, are not initiated w ithout IRB review and 
approval, except to eliminate appare nt immediate hazards to subjects.
5.5 Interruption of the Trial
The trial may be discontinued if new data about th e investigational product re sulting from this or 
any other trials become available; or for admini strative reasons; or on advice of the Sponsor, the 
Investigators, and/or th e IRB(s). If the trial is prematurely terminated or suspended, the Sponsor 
shall promptly inform the Investigators, the regu latory authorities, and IRB(s) of the reason for 
termination or suspension, as specified by the applicable regulatory requirements.The Investigator shall promptly inform the trial subjectsâ€™ pare nts/guardians and should assure 
appropriate therapy for and follow-up of subjects.
6 Vaccines Administered
Subjects will be administered  1 of the following vaccines:
xFluzone Quadrivalent vaccine, No Preserva tive: Pediatric Dose (0.25-mL dose), 2016â€“2017
formulation 
xFluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2016â€“2017 formulation
One or 2 doses of influenza vaccine will be administered according to ACIP guidance in effect 
during the study. If 2 doses of influenza vaccine are indicated, 1 dose will be administered during 
Visit 1 and the second dose will be administered  approximately 28 days later, during Visit 2.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 40 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 41 of 746.1 Identity of the Investigational Product
6.1.1 Identity of Trial Product
The 2016â€“2017 formulation of Fluzone Quadrivale nt vaccine (0.25-mL and 0.5-mL syringe 
presentations) is a sterile suspensi on prepared from the allantoic fl uid of chicken embryos infected 
with specific influenza virus strains. The vi rus-containing fluid is harvested and the virus 
inactivated with formaldehyde. The influenza virus is concentrated and purif ied in a linear sucrose 
density gradient solution using a continuous fl ow centrifuge. The virus is then chemically 
disrupted producing a split antigen. The split anti gen is then suspended in sodium phosphate-
buffered isotonic sodium chloride solution. Antibio tics are not used in th e manufacture of the 
vaccine. Fluzone Quadrivalent vaccine is essentially clear and slightly opalescent in color.
6.1.1.1 Composition
Each 0.25-mL and 0.5-mL dose of vaccine contains 7.5 Î¼g and 15 Î¼ g HA, respectively, of each 
antigen:
xA/California/07/2009 X-179A (H1N1)  
xA/Hong Kong/4801/2014 X-263B (H3N2) 
xB/Brisbane/60/2008 (Victoria lineage; B1)
xB/Phuket/3073/2013 (Yamagata lineage; B2)
6.1.1.2 Preparation and AdministrationFluzone Quadrivalent vaccine is a liquid preparation; as such, no diluent is required. This product 
is provided in 0.25-mL or 0.5-mL, pre-filled, single-dose syringes. The vaccine will be 
administered intramuscularly into the anterolatera l muscle of the thigh or the deltoid muscle, as 
appropriate. The vaccine must be administered within 30 minutes of removing the assigned 
vaccine from the refrigerator.
Prior to administration, all study pr oducts must be inspected visually for cracks, broken seals, 
correct label content (see  Section 6.3.1) , and extraneous particulate matter and/or discoloration, 
whenever solution and container pe rmit. If any of these conditions exists, the vaccine must not be 
administered; another dose is to be used, a nd the event is to be reported to the Sponsor. 
Subjects must be kept under observation for 20 mi nutes after each vaccin ation to ensure their 
safety, and any reactions during this period will be documented in the eCRF. Appropriate medical 
equipment and emergency medications, including ep inephrine (1:1000), must be available on site 
in the event of an anaphylactic or  other immediate allergic reaction.
6.1.1.3 Dose Selection and Timing
Fluzone Quadrivalent vaccine will be administ ered as a single 0.25-mL (Group 1) or 0.5-mL 
(Group 2) dose given on Day 0 at Visit 1. Fo r subjects for whom 2 doses are recommended per 
ACIP guidance, a second dose of the same volume as  the first dose will be administered at Visit 2 
(28 [window, 28â€“35] days after Visit 1). Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 41 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 42 of 746.1.2 Identity of Control Products
Not applicable.
6.2 Identity of Other Products
Not applicable.
6.3 Product Logistics
6.3.1 Labeling and Packaging
All study vaccine will be supplied with investigational labeling. 
6.3.2 Product Shipment, Storage, and Accountability
6.3.2.1 Product Shipment
The Clinical Logistics Coordinator will contact  a qualified unblinded qualified study staff 
member to determine the dates and times of delivery of products.
Each vaccine shipment will include a temperature- monitoring device to verify maintenance of the 
cold chain during transit. On delivery of the product to the site, the person in charge of product 
receipt will follow the instructions given in the Operating Guidelines, including checking that the cold chain was maintained during shipment (i.e., verification of the temp erature recorders). If 
there is an indication that th e cold chain was broken, this person should immediately quarantine 
the product, alert the Sanofi Pasteur representativ e, and request authorization from Sanofi Pasteur
to use the product.
6.3.2.2 Product Storage
The Investigator will designate  unblinded qualified study staff to be responsible for product 
administration.
At the site, products must be kept in a secure pla ce with restricted access. Vaccines will be stored 
in a refrigerator at a temperature ranging from +2Â°C to +8Â°C. The vaccines must not be frozen. 
The temperature must be monitored and documented (see the Operating Guidelines) for the entire 
time that the vaccine is at the trial site. In cas e of accidental freezing or disruption of the cold 
chain, vaccines must not be administered and must be quarantined, and the authorized designee 
should contact the Sanofi Pasteur representative for furt her instructions.
6.3.2.3 Product Accountability
The Authorized qualified study staff will maintain records of product delive ry to the trial site, 
product inventory at the site, the dose( s) given to each subject, and th e disposal of or return to the 
Sponsor of unused doses.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 42 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 43 of 74The necessary information on the product labels is to be entered into the source document and the 
eCRF. If applicable, information may also be entered into the subjectâ€™s vaccination card.
The Sponsorâ€™s monitoring staff will verify the trial siteâ€™s product accountability records against 
the record of administered doses in the CRFs and the communication from the IRT system.
In case of any expected or poten tial shortage of produc t during the trial, th e authorized designee 
should alert the Sanofi Pasteur repre sentative as soon as possible, so that a shipment of extra 
doses can be arranged.
6.3.3 Replacement Doses
If a replacement dose is required (e.g., because  the syringe broke or particulate matter was 
observed in the syringe), the si te personnel must either contact the IRT system to receive the 
replacement dose allocation or follow the instru ctions given in the Operating Guidelines.
6.3.4 Disposal of Unused ProductsUnused or wasted products will be returned to the Sponsor in accordance with the instructions in 
the Operating Guidelines. Product accountability will be verified throughout the trial period.
6.3.5 Recall of ProductsIf the Sponsor makes a decision to launch a retr ieval procedure, the Investigator(s) will be 
informed of what needs to be done.
6.4 Blinding and Code-breaking Procedures
The study will be performed in an observer-blinded fashion:
xUnblinded qualified study staff members who ar e not involved with safety evaluation and 
other trial procedures will pr epare and administer the vaccine.
xBlinded Investigators and study staff who c onduct safety assessments will not know which 
vaccine is administered.
xSubjects will not be informed as to which vaccine will be administered.
The place for storage of the product will be sepa rate from the place where the preparation and 
injection is performed. The Invest igator and study staff responsible for safety assessment will not 
be present during vaccination, but will be available in case of  an emergency (e.g., anaphylactic 
shock).
The IRT system vendor will be responsible for pr oviding the vaccine dose identification number 
to be received by the enrolled subject. The subjec t, the Investigator, and study staff members who
collect the safety data and laboratory personnel who analyze the blood samples will all be blinded
to the group assignment. The individual responsi ble for preparing/administering vaccine will not
be authorized to collect any safety/serology data.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 43 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 44 of 74Code-breaking procedures:
The code may be broken by the Investigator only in  the event of an SAE and if identification of 
the vaccine received could influence the treatmen t of the SAE. Code-breaking should be limited, 
to the extent possible, to the subject(s) experiencing the SAE. 
The blind can be broken by the Investigator or a sub-investigator  (medical doctor onlya), by 
contacting the IRT system as explained in the code-breaking procedures described in the
Operating Guidelines. Once the emergency has been  addressed by the site, the Investigator must
notify 1 of the Sanofi Pasteur RMOs  if a subjectâ€™s code was broken. All contact attempts with the
Sponsor prior to unblinding are to be documented in the source documents. 
A request for the code to be broken may be made: 
xby the GPV Department for reporting to health au thorities in the case of an SAE, as described 
in the International Conference on Harmonisation (ICH) E2A. In this case, the code will be 
broken only for the subject(s) in question. The information resulting from code-breaking (i.e., 
the subjectâ€™s vaccine dose/group assignment) will not be communicated to either the 
Investigator or the immediate team working on the study, except for the GPV representative.  
The IRB must be notified of c ode-breaking. All documentation pertaining to the event must be 
retained in the siteâ€™s study records and in the Sanofi Pasteur files. Any in tentional or unintentional 
code-breaking must be reported, documented, an d explained, and the name of the person who 
requested it must be pr ovided to the Sponsor. 
6.5 Randomization and Allocation Procedures
The Sponsor or designee will s upply a centralized, computer-generated randomization code.
Randomization of subjects will be performed with the permuted block method with stratification
by site, age group, and vaccination schedule. Each  subject who meets the inclusion/exclusion 
criteria will be randomly assi gned according to his/her age group and vaccination schedule, to 1 
of the 2 groups via an IRT system, according to a 1:1 ratio.
Before vaccination, authorized qualified st udy staff will contact the IRT system, enter 
identification and security information, and confir m a minimal amount of data in response to IRT 
system prompts. The IRT system will then st ate the vaccine dose identification number and 
whether the subject will be incl uded in the immunogenicity subs et. Subject numbers and vaccine 
dose identification numbers will be recorded on th e eCRFs. The full procedures for randomization 
are detailed in the Operating Guidelines. If the dose initially allocated for vaccination cannot be used (e.g., because the syringe broke or 
particulate matter was observed), authorized qua lified study staff will obtain a replacement dose 
(see Section 6.3.3) .
a  according to local regulationsSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 44 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 45 of 74Subject numbers should not be reassigned for any reason. 
6.6 Treatment Compliance
The following measures will ensure  that the vaccine doses administered comply with those planned, 
and that any non-compliance is documented so that it can be accounted for in the data analyses:
xAll vaccinations will be administered and recorded by unblinded qualified trial personnel
xAuthorized qualified study staff will maintain acc ountability records of pr oduct delivery to the 
trial site, product inventory at the site, and the disposal  of unused or wasted doses
6.7 Concomitant Medications and Other Therapies
At the time of enrollment, ongoing medications , including other therapies (e.g., blood products),
should be recorded in the sour ce document as well as new me dications prescribed for new 
medical conditions/AEs duri ng trial participation. 
Documentation in the eCRF of concomitant medi cation will be limited to  specific categories of 
medication of interest beginning on the day of vaccination. This may include medications of 
interest that were started pr ior to the day of vaccination.
Reportable medications will be collected in the eCRF  from the day of vaccination to the end of 
the solicited and unsolicited follow-up period (i .e., between Visit 1 and Visit 2 for subjects 
receiving 1 dose of study vaccine or Visit 1 an d Visit 3 for subjects receiving 2 doses of study 
vaccine) as they may impact the response to th e vaccination and impact the consistency of the 
information collected on concomitant  medications at any vaccination.
The â€œreportableâ€ medications are classifi ed according to 2 categories. These are:
xCategory 1 antipyretics, analge sics, non-steroidal anti-inflam matory drugs, corticosteroids, 
and other immune modulators. 
Note: inhaled and topical steroi ds should not be captured.
xCategory 2: Other reportable medi cations as specified in the protocol (i.e., medications related 
to exclusion criteria) and other medications as noted here. All non-study vaccines, immune 
globulins, and blood or blood-de rived products are included in this category. Other 
medications include topical anal gesics applied to the site of the blood draw and allergy 
hyposensitization therapy received within 30 da ys before study vaccination and through the 
Day 28 (window, 28 â€“35 days) visit. These therapies are permissible but nonetheless should be 
recorded as Category 2 medications . Topical analgesics should NOT be applied at the site of 
vaccination; however, if they ar e applied inadvertently to the vaccination site, they should be 
recorded as a Category 1 medication in this spec ific instance, not as a Category 2 medication.
The information reported in the eCRF for each reported medication will be limited to:
xTrade name
xGiven as treatment or as prophylaxis
xMedication categorySanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 45 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 46 of 74xStart and stop dates
Dosage and administration route will not be recorded. Homeopathic medication will not be 
recorded. Topical medication, except for topical analgesics applied to the site of the blood draw or
inadvertently applied to the vaccination site (see categorization instructions above), will not be 
recorded.
The fact that a medication was gi ven in response to an AE will be captured in the â€œAction Takenâ€ 
column of the AE only. No details will be reco rded in the concomitant medication m odule of the 
eCRF unless the medication received belongs to 1 o f the prelisted categorie s. Medications will not 
be coded.
7 Management of Samples
From subjects randomly assigned to the immunogen icity subset, blood samples for the assessment 
of antibody responses will be collected at Visit 1 and at Visit 2 for subjects receiving 1 dose of 
study vaccine, and at Visit 1 and Visit 3 for subj ects receiving 2 doses of study vaccine. See the 
Table of Study Procedures  and Section 5.1.3 for details of the sampling schedule.
7.1 Sample Collection
From subjects randomly assigned to the immunogenic ity subset, at Visit 1 and Visit 2 (or Visit 1 
and Visit 3 for subjects receiving 2 doses of vaccine), approximately 5 mL of blood will be 
collected in tubes provided by or recommended by the Sponsor. Immediately prior to the blood 
draw, the staff member performing the procedure w ill verify the subjectâ€™s identity and will attach 
the pre-printed label that contains that subjectâ€™s number and the sampling st age to the tube. It is 
preferred that the blood be taken from the lim b opposite to the one that will be used for 
vaccination, but it is not required.
7.2 Sample Preparation
Detailed instructions on how to  prepare blood samples for asse ssment of antibody response are 
contained in the Operating Guidelines provided to the site. An overview of the procedures is provided here. 
Following the blood draw, the tubes are to be le ft undisturbed, positioned vertically and not 
shaken, for a minimum of 1 hour and a maximum of  24 hours to allow the blood to clot. Samples 
can be stored at room temperature for up to 2 hours; beyond 2 hours, they must be refrigerated at 
a temperature of +2Â°C to +8Â°C up to a maximum of 24 hours. The samples are then centrifuged, and the serum is transferred to the appropriate number of aliquoting tubes. These tubes are pre-
labeled with adhesive labels that identify the study code, the subjectâ€™s number, and the sampling 
stage. 
The subjectâ€™s number and the date of sampling, th e number of aliquots obtained, and the subjectâ€™s 
parentâ€™s/guardianâ€™s consent for future use of hi s/her samples are to be specified on a sample 
identification list. These previous  items, as well as the date and time of preparation, are to be Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 46 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 47 of 74recorded in the source document. Space is provided on the sample identification list to record 
comments regarding the quality of samples. 
7.3 Sample Storage and Shipment
During storage, serum tubes are to be kept in a fr eezer whose temperature is set and maintained at 
-20Â°C or below. The temperature will be monitored and documented on the appropriate form 
during the entire trial. If it rises above -10Â°C for any period of time, the Clinical Logistics 
Coordinator must be notified. See the Op erating Guidelines for further details.
Samples will be shipped to Global Clinical Im munology (GCI) at Sanofi Pa steur. The address is 
provided in the Operating Guidelines.  
Shipments to the laboratory (GCI) will be made only after appropriate monitoring and following 
notification of the Clinical Logis tics Coordinator. Sera will be shipped frozen, using dry ice to 
maintain them in a frozen state, in the packaging container provided by the carrier. Again, temperatures will be monitored. Shipments must  be compliant with the International Air 
Transport Association (IATA) 602 regulations. 
7.4 Future Use of Stored Serum Samples for Research
Any unused part of the serum samples will be securely stored at the Sanofi Pasteur serology laboratory (GCI) for at least 5 years after the last license approval in the relevant market areas has 
been obtained for the vaccine being tested. 
Subjectsâ€™ parents/guardians will be asked to in dicate in the ICF whether they will permit the 
future use of any unused stored serum samples fo r other tests. If they refuse permission, the 
samples will not be used for any testing other than that directly related to this study. If they agree 
to this use, they will not be paid for giving permission. Anonymity of samples will be ensured. 
The aim of any possible future research is unknown today and may not be related to this particular 
study. It may be to improve the knowledge of vaccines or infectious diseases or to improve 
laboratory methods. Human genetic tests will ne ver be performed on these samples without 
individual informed consent.  
8 Clinical Supplies
Sanofi Pasteur will supply the trial sites with prot ocols, ICFs, eCRFs, diar y cards, and other trial 
documents, as well as with the following trial materi als: all study vaccines and injection materials, 
blood collection tubes, cryotubes, cryotube storage boxes, cryotube la bels, temperature recorders, 
shipping containers, rulers, and digital thermometers.
The means for performing electronic data capture (EDC) will be defined by Sanofi Pasteur. If a 
computer is provided by Sanofi Pasteur, it wi ll be retrieved at the end of the trial.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 47 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 48 of 74The Investigator will supply al l phlebotomy (except for the bl ood collection tubes, which are 
provided by the Sponsor) and centrifugation equipmen t, and biohazard and/or safety supplies. The 
biohazard and safety supplies incl ude needles and syringes, examina tion gloves, laboratory coats, 
sharps disposal containers, and absorbent countert op paper. The site will ensure that all biohazard 
wastes are autoclaved and disposed of in accord ance with local practices. The Investigator will 
also supply appropriate space in a temperature-monitored refrigerator for the storage of the 
products and for the blood samples, and appropriate space in a temperature-monitored freezer for 
serum aliquots.
In the event that additional supplies are required, study sta ff must contact Sanofi Pasteur,
indicating the quantity required. C ontact information is provided in the Operating Guidelines. 
They must allow approximately 1 week for an order to be filled and to have  the supplies sent to 
their site.
9 Endpoints and Assessment Methods
9.1 Primary Endpoints and Assessment Methods
9.1.1 Safety
The primary safety objective is presented in  Section 2.1.
9.1.1.1 Safety EndpointsRates of any fever (t HPSHUDWXUHÂ•Âƒ)>
oC]) during the 7 days after either vaccination
(Dose 1 and Dose 2 combined) in each vaccine group. 
9.1.1.2 Safety Assessment Methods
The safety assessment methods for th e primary endpoints are described in Section 9.3.1.3.
9.1.2 ImmunogenicityThere are no primary objectives for immunogenicity.
9.1.3 Efficacy
No clinical efficacy data will be obtained in the trial.
9.2 Secondary Endpoints and Assessment Methods
9.2.1 SafetyThere are no secondary objectives for safety.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 48 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 49 of 749.2.2 Immunogenicity
The secondary immunogenicit y objective is presented in Section 2.2.
9.2.2.1 Immunogenicity Endpoints
xGeometric mean titers: The HAI GMTs (for each of the 4 virus strains) at 28 (window, 28â€“35) 
days after the final vaccination.
xSeroconversion rates: The percentages of subj ects with either a pr e-vaccination titer < 10
(1/dil) and a post-vaccination titer Â•40 (1/dil), or a pre-vaccination titer Â• 10 (1/dil) and a 
Â• 4-fold increase in post-v accination titer at 28 (window, 28â€“35) days after the final 
vaccination.
9.2.2.2 Immunogenicity Assessment Methods
Antibodies to Influenza Viruses
Anti-influenza antibodies will be measured by HAI performed by Sanofi Pasteurâ€™s GCI 
department or an external testing laboratory under GCIâ€™s supervision. Se rum samples and quality 
control sera (sheep and/or human sera) will be  incubated with Sigma Type III NA to eliminate 
non-specific inhibitors. Adsorption of spontaneous anti-species agglutinins will be performed by 
incubating the serum samples and quality contro l sera with a red blood cell (RBC) suspension. 
Following this, the mixtures will be centrifuged and the supernatants containing the treated sera will be collected for testing. Ten 2-fold dilutions (starting at 1/10) of the treated serum samples 
and quality control sera will be in cubated with a previously titrat ed influenza virus solution at a 
FRQFHQWUDWLRQRIKHPDJJOXWLQDWLRQXQLW+$8È/,QIOXHQ]D YLUXVVROXWLRQZLOOQRWEHDGGHG
to the serum control wells containing only seru m and RBCs. The mixture will be incubated and a 
RBC suspension will be added. Following incubation, th e results will be read. The endpoint of the 
assay is the highest serum dilu tion in which complete inhibiti on of hemagglutination occurred. 
Each serum sample will be titrated in indepe ndent duplicates, and the 2 values, which do not 
differ by more than one 2-fold dilution, will be reported. The GMT between the 2 values will be 
calculated after the release of th e data to the Clinical Data Management (CDM) platform. The 
lower limit of quantification (LLOQ) for HAI is set at 10, the lowest serum dilution used in the 
assay i.e., 1/10. Titers below th is level are reported as < 10.
9.2.3 Efficacy
No clinical efficacy data will be obtained in the trial.
9.3 Observational Endpoints and Assessment Methods
9.3.1 SafetyThe observational safety objective is presented in Section 2.3.1.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 49 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 50 of 749.3.1.1 Safety Definitions
The following definitions are taken from the IC H E2A Guideline for Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting. 
Adverse Event:An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom or disease temporally 
associated with the use of a medi cinal product, whether or not cons idered related to the medicinal 
product. Therefore an AE may be:
xA new illness
xThe worsening of a concomitant illness
xAn effect of the vaccina tion, including the comparator
xA combination of the above
All AEs include serious and non-serious AEs.Surgical procedures are not AEs; they are the ac tion taken to treat a medical condition. It is the 
condition leading to the action taken that is the AE (if it occurs during the trial period).
Pre-existing medical conditions ar e not to be reported as AEs.  However, if a pre-existing 
condition worsens in frequency or intensity, or if in the assessme nt of the treating physician there 
is a change in its clinical significance, this change should be re ported as an AE (exacerbation). 
This applies equally to recu rring episodes of pre-existing conditions (e.g., asthma) if the 
frequency or intensity in creases post-vaccination. 
Serious Adverse Event:
Serious  and severe are not synonymous. The term severe is often used to describe the intensity of 
a specific event as corre sponding to Grade 3. This is not the same as serious  which is based on 
patient/event outcome or action criteria usually as sociated with events that pose a threat to a 
patientâ€™s life or functioning. Serious ness, not severity, serves as a guide for defining regulatory 
reporting obligations.
An SAE is any untoward medical  occurrence that at any dose 
xResults in death
xIs life-threateninga
aThe term â€œlife-threateningâ€ refers to an event in which the subject was at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it were more severe.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 50 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 51 of 74xRequires inpatient hospitalization or prolongation of existing hospitalizationa
xResults in persistent or significant disability/incapacityb
xIs a congenital anomaly/birth defect
xIs an important medical eventc
Additionally, the following important  medical events are to be considered as SAEs and reported 
to the Sponsor according to the procedure described in Section 10:
xNew onset of GBS, encephalitis/myelitis (including transverse myelitis), neuritis (including 
Bellâ€™s palsy, optic neuritis, and brachial neurit is), thrombocytopenia, vasculitis, convulsions 
(including febrile convulsions), and anaphylaxis or other hyper sensitivity/allergic reactions 
Adverse Reaction:
All noxious and unintended responses to a medicinal product related to any dose should be 
considered ARs.
(The phrase â€œresponses to a medicinal productâ€ means that a causal relationship between a 
medicinal product and an AE is at least a reasonable possibility.)
Unexpected Adverse Reaction:
An unexpected AR is an AR, the nature or severity  of which is not consistent with the applicable 
product information (e.g., Investigatorâ€™s Brochu re for an unapproved investigational medicinal 
product). 
The following additional definiti ons are used by Sanofi Pasteur:
Solicited Reaction:
A solicited reaction is an event that is prelis ted in the eCRF. The assessment of these AEs post-
vaccination is mandatory. A solicited r eaction is defined by a combination of:
xSymptom and
xOnset post-vaccination
Examples of solicited reactions include injec tion site pain between Day 0 and Day 7 post-
vaccination, or headache between Day 0 and Day 7. 
aAll medical events leading to hospitalizations will be re corded and reported as SA Es, with the exception of: 
hospitalization planned before inclusion into the study or outpatient treatment with no hospitalization. 
bâ€œPersistent or significant disability or incapacityâ€ means that there is a substantial disruption of a personâ€™s ability 
to carry out normal  life functions.
cMedical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in 
other situations, such as important medical events that may not be immediately life-threatening or result in death 
or hospitalization but may jeopardize the health of the s ubject or may require intervention to prevent one of the 
other outcomes listed in the definition above. These should also usually be considered serious. Examples of such 
events include allergic bronchospasm requiring intensiv e treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient  hospitalization, the development of drug dependency or 
drug abuse, or new-onset diabetes or autoimmune disease .Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 51 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 52 of 74A solicited reaction is therefore an AR observe d and reported under the conditions (symptom and 
onset) prelisted (i.e., solicited) in the eCRF  and considered as related to vaccination.
Unsolicited AE/AR:
An unsolicited AE is an observed AE that does not  fulfill the conditions prelisted in the eCRF in 
terms of diagnosis and/or onset post-vaccinati on. For example, if headache between Day 0 and 
Day 7 is a solicited reaction (i.e., prelisted in the eCRF), then a headache starting on Day 7 is a 
solicited reaction, whereas headache starting on Day 8 post-vaccination is an unsolicited AE.
An unsolicited non-serious AE is an  unsolicited AE excluding SAEs.
Injection Site Reaction:An injection site reaction
ais an AR at and around the injection site. Injection s ite reactions are 
commonly inflammatory reactions. 
Systemic AE:
Systemic AEs are all AEs that are not injection site reactions. They ther efore include systemic 
manifestations such as headache, fever, as well as localized or topical mani festations that are not 
associated with the vaccination site (e.g., erythema th at is localized but that is not at the injection 
site).
Adverse Events of Special Interest:
AEs of special interest are AEs that are cons idered by the Sponsor to  be relevant for the 
monitoring of the safety profile of the investigational vaccine. 
9.3.1.2 Safety Endpoints
The observational endpoints for the evaluation of safety are:
1)Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred 
term), duration, intensity, and relationship to vaccination of any unsolicited systemic AEs 
reported in the 20 minutes after each vaccination.
2)Occurrence, time to onset, number of days of occurrence, intensity, action taken, and whether 
the reaction led to early termination from the study, of solicited inje ction site reactions 
(prelisted in the subjectâ€™s diary card and eCRF) occurring between Day 0 and Day 7 after 
each vaccination.
3)Occurrence, time to onset, number of days of occurrence, intensity, action taken, and whether 
the reaction led to early termination from the study, of solicited systemic reactions (prelisted 
in the subjectâ€™s diary card and eCRF) occu rring between Day 0 and Day 7 after each 
vaccination.
4)Occurrence, nature (MedDRA pref erred term), time to onset, duration, intensity, action taken, 
relationship to vaccination (for systemic AE s only), and whether th e event led to early 
aAll injection site AEs are considered to be  related to vaccination; therefore, all injection site AEs are injection site 
reactions .Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 52 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 53 of 74termination from the study, of unsolicited AE s between Visit 1 and Visit 2 for subjects 
receiving 1 dose or between Visit 1 and Visit 3 for subjects receiving 2 doses.
5)Occurrence, nature (MedDRA preferred term), ti me to onset, seriousness  criteria, relationship 
to vaccination, outcome, and whether the SAE le d to early termination from the study, of 
SAEs between Visit 1 and Visit 2 for subjects receiving 1 dose or between Visit 1 and Visit 3 
for subjects receiving 2 doses.
Adverse events of special interest will be captu red as SAEs. These include new onset of GBS, 
encephalitis/myelitis (including transverse myelit is), neuritis (including Bellâ€™s palsy, optic 
neuritis, and brachial neuritis),  thrombocytopenia, vasculitis , convulsions (including febrile 
convulsions), and anaphylaxis or other hypersensi tivity/allergic reactions between Visit 1 and 
Visit 2 for subjects receiving 1 dose, or between Vi sit 1 and Visit 3 for subjects receiving 2 doses. 
9.3.1.3 Safety Assessment Methods
At Visit 2 and Visit 3 (for subjects receiving 2 infl uenza doses), the Investigator or a delegate will 
ask the parent/guardian about a ny solicited reactions a nd unsolicited AEs recorded in the diary 
card, as well as about any other AEs that may have occurred since the previ ous visit. All relevant 
data will be transcribed into the eCRF accord ing to the instructions provided by the Sponsor.
9.3.1.3.1 Immediate Post-vaccination Surveillance PeriodSubjects will be kept under observation for 20 minutes after each vaccination to ensure their 
safety. The post-vaccination surv eillance should be documented in the source document. Any AE 
that occurs during this period will be noted on the source document and recorded in the eCRF, as 
follows:
xAny unsolicited systemic AE occurring during the first 20 minutes post-vaccination will 
be recorded on the eCRF as an im mediate unsolicited systemic AE. 
xSolicited and unsolicited injection site reacti ons and solicited systemic reactions will be 
recorded and analyzed as starting on the day of vaccination. 
xAny SAE occurring during the first 20 minutes  post-vaccination will be reported in the 
same way as any other SAE and to the Sponsor , according to the procedures described in 
Section 10.
9.3.1.3.2 Reactogenicity (Solicited Reacti ons From Day 0 to Day 7 After Each
Vaccination)
After each vaccination, the subjectâ€™s parent/guardian will be provided with a safety diary card, a 
digital thermometer, and a flexible ruler, and w ill be instructed how to use them. The following 
items will be recorded by the parent/guardian in  the diary card on the day of vaccination and for 
the next 7 days (i.e., Day 0 to Day 7) until resolution:
xDaily temperature, with the route by which it was taken
xDaily measurement or intensity grade of all other solicited injection site and systemic 
reactionsSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 53 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 54 of 74xAction taken for each event, if any (e.g., medication)
The action taken by the subjectâ€™s parent/guardian to treat any solicited reactions will be classified 
in the eCRF using the following scale:
0: None
1: Medication (self-medication with an existi ng prescription or over-the-counter medication)
2: Health care provider contact (no new medication prescribed)
3: Health care provider contact  and prescription of a new me dication (health care provider 
instructed subject to take a new medication, either an over- the-counter medication or one 
requiring a written prescription)
4: Hospitalization (inpatient)
Parents/guardians will be contacted by telephon e approximately 8 days after each vaccination to 
remind them to record all safety information in the diary card.If the timing of the telephone cal l should fall on a weekend or a holiday, the call should be made 
on the next business day. If contact is not made  on the designated day, study staff will continue 
calling until contact is made. Every telephone atte mpt and its outcome will be documented in the 
source document.Table 9.1 andTable 9.2 present, respectively, the injection si te reactions and systemic reactions 
that are prelisted in the diary cards and eCRF, together with the intensity scales.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 54 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 55 of 74Table 9.1: Solicited Injection Site Reactions: Terminology, Definitions, and Intensity Scales (Subjects 6 to < 36 Months of Age)
eCRF term 
(MedDRA lowest 
level term [LLT])Injection site tenderness Injection si te erythema Injection site swelling
Diary card term Tenderness Redness Swelling
Definition Presence of redness including the 
approximate point of needle entrySwelling at or near the injection site
Swelling or edema is caused by a fluid 
infiltration in tissue or cavity and, 
depending on the space available for the fluid to disperse, sw elling may be either 
soft (typically) or firm (less typical) to touch and thus can be best described by 
looking at the size of the swelling
Intensity scaleaGrade 1: Minor reaction when injection site is touched
Grade 2: Cries or protests when injection site 
is touched
Grade 3: Cries when injected limb is moved, 
or the movement of the injected limb is 
reducedGrade 1: > 0 to < 25 mm
GradeÂ•25 to < 50 mm
GradeÂ•50 mm
aFor the subjective reaction of tenderness, parents/guardians will reco rd the intensity level (Grade 1, 2, or 3) in the diary card . For the measurable reactions of redness and 
swelling, they will record just the size of the reac tion, and the classification as Grade 1, 2, or 3 will be assigned at the tim e of the statistical analysis.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 55 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 56 of 74Table 9.2: Solicited Systemic Reactions: T erminology, Definitions, and Intensity Scales  (Subjects 6 to < 36 Months of Age)
eCRF term 
(MedDRA lowest 
level term [LLT])Fever Vomiting Crying abnormal Drowsiness Appetite lost Irritability
Diary card term Temperature Vomiting Abnormal crying Drowsiness Loss of appetite Irritability
Definition Elevation of 
temperature to Â•Â°38.0Â°C 
Â•100.4Â°F)Vomiting does not include spitting upInconsolable crying without a reasonReduced interest in surroundings, or increased sleepingSee intensity scale An excessive response to stimuli: increased fussiness, whining, and 
fretfulness despite 
attempts to comfort the infant and despite 
caregiver responses that 
would normally be soothing
Intensity scaleaGrade 1: Â• Âƒ&WRÂ” 38.5Â°C
or
Â•Âƒ)WRÂ” 101.3Â°FGrade 1: 1 episode per 
24 hoursGrade 1: < 1 hour Grade 1: Sleepier than 
usual or less interested in surroundingsGrade 1: Eating less 
than normalGrade 1: Easily 
consolable
Grade 2:>Âƒ&WRÂ” 39.5Â°C
or 
!Âƒ)WRÂ”Âƒ)Grade 2: 2â€“5 episodes 
per 24 hoursGrade 2: 1â€“3 hours Grade 2: Not interested
in surroundings or did not wake up for a 
feed/mealGrade 2: Missed 1 or 2 
feeds/meals completelyGrade 2: Requiring 
increased attention
Grade 3:
> 39.5Â°C
or
>1 0 3 . 1 Â° FGradeÂ•6 episodes 
per 24 hours or 
requiring parenteral 
hydrationGrade 3: > 3 hours Grade 3: Sleeping most of the time or difficult to wake upGrade5HIXVHVÂ•
feeds/meals or refuses most feeds/mealsGrade 3: Inconsolable
aFor all reactions but fever, parents/guardians will record the intens ity level (Grade 1, 2, or 3) in  the diary card. For fever, t hey will record the body temperature, and the 
classification as Grade 1, 2, or 3 will be assi gned at the time of the statistical analysis.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 56 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 57 of 74Important notes for the accurate assessment of temperature:
Parents/guardians are to measure body temperature once per day, preferably always at the same 
time. The optimal time for measurement is the evening, when body temperature is the highest. 
Temperature is also to be measured at the ti me of any apparent fever. The observed daily 
temperature and the route of measurement are to be recorded in the diar y card, and the highest 
temperature will be recorded by the site in the eCRF. The preferred route for temperature 
measurement in this trial is rectal. In cases wher e a rectal temperature cannot be obtained, a non-
preferred route (e.g., axillary) may be used. Pre-vaccination temperature is also to be 
systematically collected by the Investigator in th e eCRF for all subjects. Tympanic thermometers 
must not be used. 
9.3.1.3.3 Unsolicited Non-serious Adverse Events  From Visit 1 to Visit 2 or Visit 3
In addition to recording solicited reactions, the pa rent/guardian will be instructed to record any 
other medical events that may occur from Visit 1 to Visit 2 (Diary Card 1) for all subjects and 
from Visit 2 to Visit 3 (Diary Card 2) for subjec ts receiving 2 doses. Space will be provided in the 
diary card for this purpose. For each unsolicite d non-serious AE, the following information is to 
be recorded:
xStart and stop datesa
xIntensity of the event:
xFor measurable unsolicited non-serious AEs that are part of the list of  solicited reactions, 
the size of the AE as well as the temperatur e for fever will be collected and analyzed 
based on the corresponding scale used for solicited reactions (see Table 9.1 andTable 
9.2)
xOther unsolicited non-serious AEs will be classified according to the following intensity 
scale:
xGrade 1: No interference with activity
xGrade 2: Some interference with activity
xGrade 3: Significant; prevents daily activity
xAction taken for each AE, if any (e.g., medication)
The action taken by the pare nt/guardian to treat any unsolicited AEs will be classified in the 
eCRF using the following scale:
0: None
1: Medication (self-medication with an existi ng prescription or over-the-counter medication)
2: Health care provider contact (no new medication prescribed)
aThe stop date of all related AEs will be actively solicited.  For other events, the Investigator will provide the stop 
date when it becomes available. Adverse events for which no  stop date was obtained during the course of the trial 
will be considered as ongoing at the end of the trial.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 57 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 58 of 743: Health care provider contact  and prescription of a new me dication (health care provider 
instructed subject to take a new medication, either an over- the-counter medication or one 
requiring a written prescription)
xWhether the AE led to discontinuation 
xWhether the AE was related to vacci nation (for unsolicited systemic AEs)
9.3.1.3.4 Serious Adverse Events
Information on SAEs will be collected and assessed  throughout the trial, from Visit 1 until Visit 2 
(or from Visit 1 to Visit 3 for t hose subjects receiving 2 doses). 
Any SAE occurring at any time during the trial wi ll be reported by the In vestigator through the 
EDC system and according to the completion guidelines provided by the Sponsor. All information 
concerning the SAE is to be reported, either as part of the initial repo rting or during follow-up
reporting if relevant information became available later (e.g., outcome, medical history, results of 
investigations, copy of hos pitalization reports). The Investigator will assess the causal relationship 
between the SAE and the investig ational product as eith er â€œNot relatedâ€ or â€œRelatedâ€, as 
described in Section 9.3.1.3.6.
See Section 10 for further details on SAE reporting.
9.3.1.3.5 Adverse Events of Special Interest
Adverse events of special interest will be captu red as SAEs. These include new onset of GBS, 
encephalitis/myelitis (including transverse myelit is), neuritis (including Bellâ€™s palsy, optic 
neuritis, and brachial neuritis), thrombocytopenia, vasculitis, convulsions (including febrile 
convulsions), and anaphylaxis or other hypersensi tivity/allergic reactions between Visit 1 and 
Visit 2 for subjects receiving 1 dose, or between Vi sit 1 and Visit 3 for subjects receiving 2 doses. 
9.3.1.3.6 Assessment of Causality 
At each visit, the Investigator or a delegate will perform a directed examination, if indicated, 
based on interim history, and will ask the parent/guardian about any solicited reactions and 
unsolicited AEs recorded in the diary card, as we ll as about any other AEs that may have occurred 
since the previous visit. All re levant data will be transcribe d into the eCRF according to the 
instructions provided by the Sponsor.
The Investigator will assess the causal relationship between each unsolicited systemic AE and 
vaccination as either not related or related, based on the following definitionsa:
0: Not related â€“ The AE is clearly/most probabl y caused by other etiologies such as subjectâ€™s 
underlying condition, therapeutic intervention, or concomitant therapy; or the delay 
between vaccination and the onset of the AE is incompatible with a causal relationship; or 
the AE started before the first vacci nation (screening phase, if applicable)
aICH Guidelines, Clinical Safety Data Management E2ASanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 58 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 59 of 741:  Related â€“ There is a â€œreasonable possibili tyâ€ that the AE was caused by the vaccination, 
meaning that there is evidence or argu ments to suggest a causal relationship
Note: By convention, all injection site AEs (so licited and unsolicited) an d all solicited systemic 
reactions are considered to be related to vaccina tion and referred to as reactions, and therefore do 
not require the Investigato râ€™s opinion on relatedness.
Adverse events likely to be relate d to the product, whethe r serious or not, that persist at the end of 
the trial will be followed up by the Investigat or until their complete disappearance or the 
stabilization of the subjectâ€™s cond ition (unless the subjectâ€™s parent /guardian specified that they do 
not want to be contacted for follow-up and it is documented in the source document). The 
Investigator will inform the Sponsor of the date of final disappearance of the event.
9.3.2 Immunogenicity
The observational immunogenicity objective is presented in Section 2.3.2.
9.3.2.1 Immunogenicity Endpoints
Immunogenicity will be evaluated in a subset of 1600 randomly select ed subjects prior to 
vaccination on Day 0 (Visit 1) and at 28 (window, 28â€“35) days after the final vaccination using 
the HAI technique. For each influenza vaccine strai n, HAI assay titers at pre-vaccination (Day 0) 
and at 28 (window, 28â€“35) days after the final vaccination will be determined in duplicate. The derived endpoints are:
xGeometric means of HAI assay titers for individua l subjects at pre-vaccination (Day 0) and at 
28 (window, 28â€“35) days after the final vaccination.
xRatios of individual post-final vaccination titer s divided by individual pre-vaccination titers.
x6HURSURWHFWLRQVXEM HFWVZLWKDWLWHUÂ• 40 (l/dil) at pre- vaccination or at 28 (window, 28â€“35) 
days after the final vaccination.
xSeroconversion: subjects with ei ther a pre-vaccination titer < 10 (1/dil) and a post-vaccination 
titer Â• 40 (1/dil), or a pre-vaccination titer Â• 10 (1/dil) and a Â•4-fold increase in post-
vaccination titer at 28 (window, 28â€“35) days after the final vaccination.
9.3.2.2 Immunogenicity Assessment Methods
The immunogenicity assessment methods for the observational endpoints are the same as those 
presented in Section 9.2.2.2.
9.3.3 EfficacyNo clinical efficacy data will be obtained in the trial.
9.3.4 Serum Collection
The observational objective for se rum collection is presented in Section 2.3.3.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 59 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 60 of 749.3.4.1 Serum Collection Endpoints and Assessment Methods
There are no observational endpoint s for the serum collection objective.
10 Reporting of Serious Adverse Events  
To comply with current regulati ons on SAE reporting to health aut horities, the Investigator must 
document all SAEs regardless of causal relations hip, and notify the Sponsor and the Clinical 
Research Associate (CRA) within the notification timelines stated in the following sections. The 
Investigator will give access and provide the Spon sor and the CRA with al l necessary information 
to allow the Sponsor to conduct a detailed analysis of the safety of the investigational product(s). 
It is the responsibility of the Investigator to request all necessary docum entation (e.g., medical 
records, discharge summary, autopsy) to provide comprehensive safety information. All relevant 
information must then be transcribed into the electronic SAE reporting form (eSAE Form).
10.1 Initial Reporting by the Investigator
Serious adverse events occurring during a subjectâ€™ s participation in the trial must be reported 
within 24 hours to the Sponsorâ€™s GPV Department  and to the CRA. Every SAE must be reported, 
even if the Investigator considers that it is not related to the vaccine. The SAE form must be 
signed by a licensed physician (MD or DO) for whom the task is listed on the Study Task Delegation and Signature List afte r each update to the eSAE Form.
The Investigator must complete the eSAE Form  in the EDC application. After validation, an 
e-mail alert will automatically be sent to  the GPV mailbox, the CRA, and the RMOs. This 
message will include the country, the study code, the subject number, whether the report is an 
initial report or a follow-up report,  the diagnosis and/or symptoms , the seriousness criteria, the 
relationship, if related, a nd the outcome, if fatal. 
If the EDC system is unavailable, the site must notify the Sponsor using the paper version of the 
SAE Reporting Form, as follows: 
The Investigator must complete the SAE Reportin g Form, check off the â€œInitial Reporting Formâ€ 
box, and send it to the Sponsor by 1 of the following means: 
xBy fax, to the following number:
xIn PDF format to the following e-mail addr ess, using a method of transmission that 
includes password protection:
xBy express mail, to the following address:  
When the system becomes available, the Investig ator must transcribe th e information from the 
paper version of the eSAE Form into the EDC system. Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 60 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 61 of 74If there is need for urgent consultation, the Invest igator is to contact 1 of the RMOs as described 
in Section 5.3.
10.2 Follow-up Reporting by the Investigator
The eSAE Form completed initially must be upda ted within 24 hours after the Investigator has 
become aware of any new relevant informa tion concerning the SAE (e.g., outcome, precise 
description of medical history, re sults of the investig ation). After validation, an e-mail alert will 
be sent automatically to the GPV Department and to the CRA. All relevant information must be 
included directly in the eSAE Form. Copies of  documents (e.g., medical records, discharge 
summary, autopsy) may be requested by the GPV Department.
The anonymity of the subject must always be respected when forwarding this information.
10.3 Reporting of SAEs Occurring After a Subject Has Completed the Study
Any SAE that occurs after a subject  has completed the study but that is  likely to be related to the 
product or to the trial must also  be reported as soon as possible.  In such a case, the reporting 
procedure to be followed is id entical to that described in  Section 10.1.
10.4 Assessment of Causality
The causal relationship between the SAE and the product will first be evaluated by the 
Investigator, using the following definitions:
0 - Not related : The AE is clearly/most probably cause d by other etiologies such as an 
underlying condition, therapeutic intervention, or concomitant therapy; or the delay between 
vaccination and the onset of the SAE is incompa tible with a causal relationship; or the SAE 
started before the first vaccination (screening phase, if applicable).
1 - Related : There is a â€œreasonable possibilityâ€ that  the SAE was caused by the vaccination, 
meaning that there is evidence or argu ments to suggest a causal relationship.
(ICH Guidelines, Clinical Safety Data Management E2A)
Following this, the Sponsorâ€™s Product Safety Officer (PSO) will also assess the causal relationship to the product, based on the available in formation and current medical knowledge.
The decision to modify or disc ontinue the trial may be made after mutual agreement between the 
Sponsor and the Investigator(s). 
10.5 Reporting SAEs to Health  Authorities and IECs/IRBs
The Sponsor will inform the releva nt health authorities of any reportable SAEs according to the 
local regulatory requirements. Re porting to the health author ities will be according to the 
Sponsorâ€™s standard operating procedures.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 61 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 62 of 74The Sponsorâ€™s RMOs will notify the Investigators in writing of the occurrence of any reportable 
SAEs. The Investigators/Sponsor w ill be responsible for informing the IRBs that reviewed the 
trial protocol.
11 Data Collection and Management
11.1 Data Collection and eCRF Completion
Individual safety diary cards, sp ecifically designed for this tr ial by the Sponsor and provided to 
the study sites, will be given to study participants for the recording of daily safety information as 
described in Section 9.3.1.3. These diary cards will include prelisted terms and intensity scales 
(seeTable 9.1 andTable 9.2) as well as areas for free text to capture additional safety information 
or other relevant details. Parents/ guardians will also be provided with  rulers for measuring the size 
of injection site reactions, and with standa rd digital thermometers for measuring daily 
temperatures. To ensure consistency of reporting,  the study sites will instruct parents/guardians on 
how to correctly use these tools.
At specified intervals, the Investigator or  an authorized designee will interview the 
parents/guardians to collect the information recorded in the diary card, and will attempt to clarify 
anything that is incomplete or un clear. All clinical trial information gathered by the study site will 
be reported electronically by the Investigator or  authorized designee using a web-based eCRF. 
(Any information that was not documented in the diary card will first be captured in the source document and then reported electr onically.) The eCRF has been de signed specifically for this trial 
under the responsibility of the Sponsor, using a validated Electronic Records/Electronic 
Signature-compliant platform (21 CFR Part 11).
To ensure the correct and consis tent completion of the eCRFs, the Sponsor or authorized 
representative will provide all necessary tools, in structions, and training to all site staff involved 
in data entry prior to study start. Additional in structional documents such as training manuals and 
completion guidelines will be provided to assist with data entry during the course of the trial.Upon completion of training, each user requirin g access to the EDC system will be issued a 
unique username and password. In the event of a ch ange in trial personnel, each newly assigned 
individual will receive a unique username a nd password; the userna me and password of a 
previous user may not be reissued. If any tr ial personnel leave the study, the Investigator is 
responsible for informing the Sponsor immediately so that their access is  deactivated. An audit 
trail will be initiated in the EDC system at the ti me of the first data entry in order to track all 
modifications and to ensure database integrity.The Investigator is responsible for the timeline ss, completeness, and accuracy of the information 
in the eCRFs; must provide explanations for all missing information; and must sign the eCRF 
using an e-signature.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 62 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 63 of 7411.2 Data Management
Management of Clinical Data
Data generated during the trial will be managed following 2 different processes:
xClinical data, defined as all data reported in the eCRF, and laboratory data will be handled 
by the Sponsorâ€™s CDM platform or authorized representative.
xData pertaining to SAEs, which are reporte d by the Investigator on the eSAE Forms or 
SAE Reporting Forms, will be handled by the Sponsorâ€™s GPV Department.
During the trial, clinical data reported in the eCRF s will be integrated into the clinical database 
under the responsibility of the Sa nofi Pasteur CDM platform. Data monitoring at the sites and 
quality control in the form of computerized logic and/or consistency checks will be systematically 
applied in order to detect errors or omissions. In addition, data reviews may be performed several 
times by the Sponsorâ€™s staff in the course of th e trial. Any questions pe rtaining to the reported 
clinical data will be submitted to the Investigator  for resolution using the EDC system. Each step 
of this process will be monitored through the impl ementation of individual passwords to maintain 
appropriate database access and to ensure database integrity.
The validation of the immunogenicity data will be performed at the laboratory level following the 
laboratoryâ€™s procedures. Informa tion from the laboratory will be ch ecked for consistency before 
integration into the clinical database.
After integration of all corrections in the comp lete set of data, and af ter the SAE information 
available from the CDM platform and the GPV Department has been reconcile d, the database will be 
released for statistical analysis.
Serious Adverse Event Data Management
During the trial, data pertaining to SAEs reported on eSAE Forms will be  integrated into the 
Sponsorâ€™s centralized GPV database.
Upon receipt of an eSAE Form, the data will be  entered into the GPV database after a duplicate 
check. Each SAE case will be assigned a case identif ication number. Each case will be entered in 
the GPV database and assessed by the case management platform or its delegate before being 
reported to the relevant authorities as necessar y. Assessment of related cases will be done in 
collaboration with the PSO and the RMO(s). Follow-up information conc erning a completed case 
will be entered into the GPV database, and a new version of the case will be created.
The information pertaining to SAEs in the GPV d atabase will be reconciled with that in the 
clinical database.
11.3 Data Review
A review of the data is performed on a regular  basis through the data review process led by the 
CDM platform until the database lock.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 63 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 64 of 7412 Statistical Methods and Determination of Sample Size
12.1 Statistical Methods
Summaries of the recruitment and baseline demogr aphic characteristics of  the study subjects will 
be presented. The number of subjects enrolled and their age at enrollment (mean, median, and 
minimum and maximum), sex, race, and ethnic or igin will be summarized, along with the number 
and description of pr otocol violations.
Continuous variables will be summarized by de scriptive statistics (e.g., means and standard 
deviations for the non-immunogenicity endpoints, and geometric means and their CIs for the 
immunogenicity endpoints); categorical variables will be summarized by frequency distributions (frequency counts, percentages, and their CIs for the main endpoints).
12.1.1 Hypotheses and Statistical Methods for Primary Objective
12.1.1.1 Hypothesis
During the 7 days after either vaccination (Dose 1 and Dose 2 combined), the 0.5-mL dose of 
Fluzone Quadrivalent vaccine will be non-inferior  to the 0.25-mL dose of Fluzone Quadrivalent 
vaccine in terms of fever reaction (t HPSHUDWXUHÂ•Âƒ)>
oC]) in subjects 6 to < 36 months 
of age.
12.1.1.2 Statistical Methods
The 0.5-mL dose of Fluzone Quadrivalent vaccine will be demonstrated as non-inferior to the 
0.25-mL dose of Fluzone Quadrivalent vacc ine in terms of fe ver reaction through an assessment
RIWKHUDWHVRIDQ\IHYHUWHPSHUDWXUHÂ•Âƒ)>oC]) during the 7 days following any dose 
(Dose 1 and Dose 2 combined). Non-inferiority will be demonstrated if the upper bound of the 
2-sided 95% CI of the rate difference between Group 2 (subjects receiving 0.5 mL of vaccine) 
and Group 1 (subjects receiving 0.25 mL of vaccine)  is < 5%. The 95% CI of the rate difference 
will be computed using the Wilson Score met hod without continuity correction. The Safety 
Analysis Set will be used for this objective.
12.1.2 Hypotheses and Statistical Methods for Secondary Objective
12.1.2.1 Hypotheses
xGeometric mean titers: For each of the 4 virus st rains, the post-final vaccination GMTs in 
subjects 6 to < 36 months of age who rece ive the 0.5-mL dose of Fluzone Quadrivalent 
vaccine will be non-inferior to the post-final vaccination GMTs in those subjects who receive 
the 0.25-mL dose of Fluzone Quadrivalent vaccine.
xSeroconversion: For each of the 4 virus stra ins, the seroconversion rates in subjects 
6 to < 36 months of age who receive the 0.5-mL dos e of Fluzone Quadrivalent vaccine will be Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 64 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 65 of 74non-inferior to the seroconversion rates in t hose subjects who receiv e the 0.25-mL dose of 
Fluzone Quadrivalent vaccine. 
12.1.2.2 Statistical Methods
xGeometric mean titers: The statistical methodol ogy will be based on a 2-sided 95% CI of the 
ratio of the GMTs (0.5-mL dose divided by 0.25-mL dose) at 28 (window, 28â€“35) days after 
the final vaccination.  Non-inferiority for GMTs will be demonstrated if the lower limit of the 
2-sided 95% CI of the GMT ratio is > 0.667 for each of the 4 virus strains. The 95% CI will be 
calculated using normal approximation of log-tr ansformed titers. The Per-Protocol Analysis 
Set (PPAS) will be used as the primary analysis set for this objective.
xSeroconversion: The statistical methodology will  be based on a 2-sided 95% CI of the 
difference in seroconversion rates (0.5-mL dose minus 0.25-mL dose) at 28 (window, 28â€“35) days after the final vaccination. Non-inferiority for seroconversion will be demonstrated if the 
lower limit of the 2-sided 95% CI is > -10% for the 4 strains. The 95% CI of the rate difference will be computed using the Wilson Score method without continuity correction. 
The PPAS will be used as the primary analysis set for this objective.
12.1.3 Statistical Methods for Observational Objectives
12.1.3.1 Safety
. 
12.1.3.2 Immunogenicity
The following immunogenicity parameters will be calculated for each influenza strain with 
95% CIs of point estimates calculated using the exact binomial distribution (Clopper-Pearson 
method) for proportions and using normal approximation for GMTs: 
xGeometric mean HAI assay tite rs at pre-vaccination (Day 0)  and at 28 (window, 28â€“35) days 
after the final vaccination.
xGeometric means of the individual titer ratios of post-final vacci nation/pre-vaccination.
xSeroprotection rates: The percentage VRIVXEMHFWVZLWKDWLWHUÂ• 40 (l/dil) at pre- vaccination and 
at 28 (window, 28â€“35) days af ter the final vaccination. 
xSeroconversion rates: The percentages of subjects with either a pre-vaccination titer 
< 10 (1/dil) and a post-vaccination titer Â•40 (1/dil), or a pr e-vaccination titer Â•10 (1/dil) and 
aÂ• 4-fold increase in post-vac cination titer at  28 (window, 28 â€“35) days after the final 
vaccination. Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 65 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 66 of 7412.2 Analysis Sets
Three main analysis sets will be used: the Safety Analysis Set, the Full Analysis Set (FAS), and 
the PPAS.
12.2.1 Safety Analysis Set 
The Safety Analysis Set is defined as those subjects who have received study vaccine.aAll 
subjects will have their safety analyzed after any dose according to the vaccine they actually 
received at the first dose. Safety data recorded  for a vaccine received ou t of the protocol design 
will be excluded from the analysis (and listed separately).
Safety analysis after each dose will be assessed in  the subset of the Safety Analysis Set having 
received that dose. All subjects will have their safety data analyzed after each vaccination 
according to the vaccine they actu ally received at this dose.  
12.2.2 Full Analysis Set
.
12.2.3 Per-Protocol Analysis Set
xSubject did not meet all protocol -specified inclusion criteria or met at least 1 of the protocol-
specified exclusion criteria 
xSubject did not receive vaccine or did not comple te the vaccination schedule as per protocol 
xSubject received a vaccine dose other than the one that he/she was randomly assigned to 
receive
xPreparation and/or administration of vaccine was not done as per protocol 
xSubject did not receive vacci ne in the proper time window 
xSubject was randomly assigned to the immunogeni city subset, but did not provide a post-dose 
serology sample in the proper time window or a post-dose serology sample was not drawn 
xSubject received a protocol-prohibited thera py/medication/vaccine that might impact antibody 
response to the study vaccine 
xSubjectâ€™s post-vaccinatio n serology sample did not produce a valid HAI test result for any 
strain
a  for which safety data are scheduled to be collected Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 66 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 67 of 74xAny other deviation identified during conduct of  the study conduct and judged by the clinical 
team during data review as having a potential impact on th e assessment of immunogenicity 
12.2.4 Populations Used in Analyses 
Baseline and demographic analyses will be performed on all enrolled subjects.
The safety analyses will be perf ormed on the Safety Analysis Set.
The immunogenicity analyses will be perfor med on both the FAS and PPAS. The PPAS will be
the primary analysis set for non-inferiority demonstration.
12.3 Handling of Missing Data and Outliers
12.3.1 Safety
No replacement of missing data wi ll be done. All subjects with safety data and all safety data 
recorded in the eCRFs will be included in the safety analyses. No search for outliers will be 
performed. 
12.3.2 Immunogenicity
12.4 Interim/Preliminary Analysis
No interim analyses are planned. 
12.5 Determination of Sample Size and Power CalculationSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 67 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 68 of 7413 Ethical and Legal Issues and Investigator/Sponsor Responsibilities
13.1 Ethical Conduct of the T rial/Good Clinical Practice
The conduct of this trial will be consistent with  the standards establishe d by the Declaration of 
Helsinki and compliant with the ICH guidelines fo r GCP as well as with a ll local and/or national 
regulations and directives.
13.2 Source Data and Source Documents
â€œSource dataâ€ are the data cont ained in source documents. So urce documents are original 
documents or certified copies, and include, but are not limited to, diary cards, medical and 
hospital records, screening logs, informed c onsent/assent forms, telephone contact logs, and 
worksheets. The purpose of trial source documents is  to document the existence of subjects and to 
substantiate the integrity of the trial data colle cted. Investigators must maintain source documents 
so that they are accurate, comp lete, legible, and up to date. 
For missing or discrepant data on a diary card, th e study coordinator will obtain verbal clarification
from the subject, enter the respons e into the â€œInvestigatorâ€™s commen tâ€ page of the diary card, and 
transfer the information to the eCRF.
The subject pre-screenin g log should list all individuals c ontacted by the I nvestigators to 
participate in the trial, regardless of the outcome.The Investigator must print
a any electronic records on an ongoi ng basis, sign and date them 
immediately after creation, and keep the printouts on file as source doc uments that can be verified 
by the Sponsor or an inspector ag ainst the electronic records. A ny later changes of  an electronic 
record require the record to be re-printed, dated (with an indicati on of the date of change), and 
signed. Such records must also be kept together with the or iginal printed copy. 
13.3 Confidentiality of Data and Access to Subject Records
Prior to initiation of the trial, the Investigator  will sign a fully executed confidentiality agreement 
with Sanofi Pasteur. 
a  Unless the electronic medical records are managed by va lidated computerized systems that are compliant with US 
21 CFR Part 11, in which case they are acceptable on their own.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 68 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 69 of 74Sanofi Pasteur personnel (or designates), the IRBs , and regulatory agencies, including the FDA, 
require direct access to all study records, and will treat these documents in a confidential manner.
In the event a subjectâ€™s medical re cords are not at the investigational site, it is the responsibility of 
the Investigator to obtain those records if needed.
13.4 Monitoring, Auditing, and Archiving
13.4.1 Monitoring
Before the start of the trial (i.e., before the in clusion of the first subj ect in the first center), the 
Investigators and the Sponsorâ€™s staff or a represen tative will meet at the site-initiation visit to 
discuss the trial protocol and th e detailed trial procedures. Empha sis will be placed on promoting 
understanding of inclusion and ex clusion criteria, visit timing, safety procedures, informed 
consent procedures, SAE reporting procedures, eCRF completion, and the handling of samples 
and products. The Sponsorâ€™s staff or a representative will ensure and document that all material to 
be used during the trial has been received at the site; and that th e study investigator team and local 
Sponsor/delegate staff have been properly in formed about the trial, GCP and regulatory 
requirements, and the Sponsorâ€™s procedures. Specif ic training sessions fo r the study investigator 
team and the CRAs on these topics may be perf ormed as necessary, and should be documented.
The following instruction manuals will be provided: the eCRF Completion Guidelines for 
entering data into the eCRF, and the Operating Guid elines for detailing trial procedures such as 
those related to product manageme nt and the handling of samples.
After the start of the trial, the Sponsorâ€™s staff or a representative will be in  regular contact with the 
investigational team through tele phone calls and regular follow- up visits. The Investigator or 
delegate must be available for these visits and must allow the Sponsor/delegate staff direct access 
to subject medical files and eCRFs. During these visits, the Spons or/delegate staff will:
xEvaluate the quality of the trial progress (a dherence to protocol and any study-specific 
guidelines, quality of data collection and document completion, presence of appropriate 
signatures on consent forms, occurrence of SAEs, sample and product management, cold-chain monitoring, archiving)
xSource-verify completed eCRFs and any corresponding answered queries
xDetermine the number of complete or ongoing is sues identified at monitoring visits (e.g., 
protocol deviations, SAEs). Any identified proble ms will be discussed with the Investigator,
and corrective or preventive actions will be determined, as appropriate.
xAfter all protocol procedures have been comple ted and the data have been entered into the 
eCRF, the Investigator must sti ll be available to answer any queries forwarded by the Sponsor. 
All data-related queries must be completed prior to database lock. 
At the end of the trial, a close-out vi sit will be performed to ensure that:
xThe center has all the documents necessary for archiving
xAll samples have been shipped to  the appropriate laboratory (GCI)
xAll unused materials and products have been ei ther destroyed or returned to the SponsorSanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 69 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 70 of 7413.4.2 Audits and Inspections
A quality assurance audit may be performed at any time by the Sponsorâ€™s Clinical and Medical 
Quality Operations Department or by independent auditors to verify that the trial has been 
conducted according to the protocol, GCP a nd ICH requirements, and other applicable 
regulations. An inspection may be conducted by regulatory authorities. The Investigator must 
allow direct access to trial documents during these inspections and audits.
13.4.3 Archiving
The Investigator must keep all trial documents af ter the completion or discontinuation of the trial,
whatever the nature of the inves tigational center (private practice,  hospital, or in stitution), for as 
long as required by applicable la ws and regulations. In the absen ce of any applicable laws or 
regulations, trial documents will be kept at a minimum for the duration indicated on the Clinical 
Trial Agreement (CTA). In no event, should study personnel destroy or permit the destruction of any trial documents upon less than 90 days adva nce written notificati on to the Sponsor. In 
addition, trial documents should continue to be store d, at Sponsorâ€™s sole expe nse, in the event that 
the Sponsor requests in writing that such storage continues for a period of time that exceeds that 
required by any applicable law or regulation or  the CTA. The Investigator will inform Sanofi 
Pasteur of any address change or if they will no longer be able to house the trial documents.
Archived data may be held on electronic records,  provided that a back-up exists and that a hard 
copy can be obtained if requi red. The protocol, documenta tion, approvals, and all other 
documents related to the trial, including certificates attesting that satisfactory audit and inspection procedures have been carried out, will be kept by  the Sponsor in the Trial Master File (TMF). 
Data on AEs are included in the TMF. All data and documents will be made available if requested by relevant authorities.
13.5 Financial Contract and Insurance Coverage
A CTA will be signed by all the parties involved in  the trialâ€™s performance, if relevant. The 
Sponsor has an insurance policy to cover any liabilities that may arise from use of the product and/or the study protocol.
13.6 Stipends for Participation
Subjects may be provided with a stipend according to local practice to compensate for the time 
and travel required for study visits and procedures.
13.7 Publication Policy
Data derived from this trial are the exclusive property of Sanofi Pasteur. Any publication or 
presentation related to the trial must be submitted to Sanofi Pasteur for review before submission of the manuscript. After publication of the results of the trial, a ny participating center may publish 
or otherwise use its own data provided that any p ublication of data from the trial gives recognition Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 70 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 71 of 74to the trial group. In addition, Sanofi Pasteur shall  be offered an association with all such 
publications, it being understood that Sanofi Pasteur is entitled to refuse the association.
Sanofi Pasteur must have the opportunity to re view all proposed abstracts, manuscripts, or 
presentations regarding this tria l at least 90 days prior to subm ission for publication/presentation. 
Any information identified by Sanofi Pasteur as c onfidential must be dele ted prior to submission, 
it being understood that the resu lts of this trial are not to  be considered confidential.
Sanofi Pasteurâ€™s review can be expe dited to meet publication guidelines.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 71 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 72 of 7414 References List
1 Centers for Disease Control and Prevention. Prevention and control of seasonal influenza 
with vaccines. Recommendations of the A dvisory Committee on Immunization Practices-
United States, 2013-14. MMW R. 2013;62(RR07):1-43.
2 Fiore AE, Bridges CB, Katz JM, Cox NJ. Inact ivated influenza vaccines. In: Plotkin SA, 
Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Edinburgh, UK: Elsevier/Saunders; 
2012;257-93.
3 Treanor JT. Influenza viruses,  including avian influenza and swine influenza. In: Mandell 
GL, Bennett JE, Dolin R, eds. Mandell, Douglas , and Bennett's Principl es and Practice of 
Infectious Diseases. 7th ed. New Yor k, NY: Churchill Livingstone; 2010:2265-88.
4 Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 
2010;28(suppl 4):D45-53.
5 Centers for Disease Control and Preventi on. Influenza activity - United States, 2012-13
season and composition of the 2013-14 infl uenza vaccine. MMWR . 2013;62(23):473-9.
6 Hu J-J, Kao C-L, Lee P-I, et al. Clinical features of influenza A and B in children and 
association with myositis. J Microbi ol Immunol Infect. 2004;37(2):95-8.
7 Hite LK, Glezen WP, Demmler GJ, Munoz FM . Medically attended pediatric influenza 
during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis. 
2007;11(1):40-7.
8 Glezen WP, Couch RB, Taber LH, et al. Epid emiologic observations of influenza B virus 
infections in Houston, Texas, 1976- 1977. Am J Epidemiol. 1980;111(1):13-22.
9 Centers for Disease Control and Prevention. Prevention and control of seasonal influenza 
with vaccines: recommendations of the A dvisory Committee on Immunization Practices 
(ACIP) -- United States, 2014-15 infl uenza season. MMWR. 2014;63(32):691-7.
10 Centers for Disease Control and Preventi on. Prevention and control of influenza: 
recommendations of the Advisory Committ ee on Immunization Practices (ACIP), 2007. 
MMWR. 2007;56(RR-6):1-54.
11 Mitchell DK, Ruben FL, Gravenstein S. Immunog enicity and safety of inactivated influenza 
virus vaccine in young children in 2003-2004. Pediatr Infect Dis J. 2005;24(10):925-7.
12 Salmon DA, Proschan M, Forshee R, et al. Association between Guillain-BarrÃ© syndrome 
and influenza A (H1N1) 2009 monov alent inactivated vaccines in the USA: a meta-analysis. 
Lancet. 2013;381(9876):1461-8.
13 Halasa NB, Gerber MA, Berry AA, et al. Safe ty and immunogenicity of full-dose trivalent 
inactivated influenza vaccine (TIV) compared with half-dose TIV admi nistered to children 
6 through 35 months of age. J Pediatr Infect Dis Soc. 2014. DOI:10.1093/jpids/piu061. 
14 Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine 
in young children. N Engl J Med. 2011;365(15):1406-16.
15 Jefferson T, Rivetti A, Di Pietrantonj C, De micheli V, Ferroni E. Vaccines for preventing 
influenza in healthy children. Coch rane Database Syst Rev. 2012;8:CD004879.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 72 of 75
Sanofi Pasteur GRC88
450â€“FluzoneÂ®Quadrivalent
Confidential/Proprietary Information
Page 73 of 7416 Treanor JJ, Talbot HK, Ohmit SE , et al. Effectiveness of seasonal influenza vaccines in the 
United States during a season with circulation of all three vaccine strains. Clin Infect Dis. 
2012;55(7):951-9.
17 Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response 
to influenza vaccine in children aged 6 to 23 months. Pediatrics. 2011;128(2):e276-89.
18 Esposito S, Marchisio P, Ansaldi F, et al. A randomized clinical trial assessing 
immunogenicity and safety of a double dose of  virosomal-adjuvanted influenza vaccine 
administered to unprimed children aged 6-35 months. Vaccine. 2010;28:6137-44.
19 Esposito S, Marchisio P, Montinaro V, et al . The immunogenicity and safety of a single 0.5 
mL dose of virosomal subunit influenza vaccin e administered to unpr imed children aged 
>/=6 to <36 months: data from a randomi zed, Phase III study. V accine. 2012;30(49):7005-
12.
20 Langley JM, Vanderkooi OG, Garfield HA, et  al. Immunogenicity and safety of 2 dose 
levels of a thimerosal-free trivalent seasona l influenza vaccine in children aged 6-35
months: a randomized, controlled trial. J Pediatr Infect Dis Soc. 2012;1(1):55-63.
21 National Advisory Committee on Immuni zation (NACI). An Advisory Committee 
Statement (ACS). Statement on seasona l influenza vaccine for 2014-2015. Canada 
Communicable Disease Report. 2014;40:1-68.
22 National Advisory Committee on Immuni zation (NACI). An Advisory Committee 
Statement (ACS). Statement on seasona l influenza vaccine for 2012-2013. Canada 
Communicable Disease Repor t. 2012;38(ACS-2):1-36.
23 Flu Vaccination Coverage, United States, 2013-14 Influenza Season. Centers for Disease 
Control and Prevention Website. http ://www.cdc.gov/flu/fluvaxview/coverage-
1314estimates.htm. Accessed 20 January 2015.
24 Singleton JA and Kennedy ED. Influenza v accination coverage, United States, 2011-12
season. ACIP presentation, October 25, 2012. Cent ers for Disease Control and Prevention 
Website. http://www.cdc.gov/vaccines/acip/m eetings/meetings-info.html. Accessed 20 
January 2015.
25 Singleton JA and Kennedy ED. Influenza vacc ination distribution and coverage, United 
States, 2012-13 season. ACIP presentation, Oc tober 24, 2013. Centers for Disease Control 
and Prevention Website. http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html. 
Accessed 20 January 2015.
26 Ferdinands JM, Olsho LE, Agan AA, et al. Pediatric Acute Lung Injury and Sepsis 
Investigators (PALISI) Network. Effectiveness of influenza va ccine against life-threatening 
RT-PCR-confirmed influenza illness in  US children, 2010-2012. J Infect Dis. 
2014;210(5):674-83.Sanofi Pasteur 
Confidential/Proprietary Information 
     GRC88
450â€“FluzoneÂ® Quadrivalent Protocol Version 2.0
Page 73 of 75